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1. History of T2D pharmacotherapy since discovery of 
insulin and current situation
1. 1 Brief history of pharmacotherapy of T2D
100 years ago, diabetes mellitus was a lethal disease, which was possibly seen 
as worse than cancer is considered today. There were no effective treatments to 
change the fate of diabetes patients, except that starvation intervention seemed to 
slightly delay the process to death1. 
The discovery of insulin was a milestone in the history of diabetes treatment. 
Since 1922, when insulin was introduced as a clinical treatment, diabetes is no 
longer considered a severe disease2. Millions of diabetes patients are able to live 
normal lives with insulin.
However, insulin cannot solve all the problems of diabetes patients. One 
problem is that a larger dosage of insulin should be used for some patients to 
control their plasma glucose concentrations. In 1936, Prof. Himsworth published 
a paper on differentiating diabetes patients into insulin-sensitive and insulin-
insensitive types3; these are now called type 1 diabetes (T1D) and type 2 diabetes 
(T2D). T1D means the patient has a lack of insulin, while T2D means there is not 
only relatively insufficient insulin, but that it is also ineffective in utilizing the 
glucose efficiently; this is now called “insulin resistance (IR)”.
Since tolbutamide and metformin were introduced as therapy in the 1950s, 
a number of oral anti-diabetic drugs for T2D have been developed (Box 1). Each 
type of drug has its own mechanism of effect, and we now have several options 
Oral anti-diabetic drugs Mechanism
Sulfonylureas/glinides Stimulates beta-cells to secret more insulin
Metformin Inhibits hepatic glucose production
Alpha-glucosidase inhibitors Delays absorption of carbohydrates by intestine
Pioglitazon Enhances the activity of GLUT4
DPP-IV inhibitor Increases t1/2 of GLP-1
SGLT2 Increases renal glucose elimination
Box 1. Oral anti-diabetic drugs and their mechanisms
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for treating T2D4. Metformin, sulfonylureas/glinides, alpha-glucosidase inhibitors, 
thiazolidinediones and insulin constitute the current pharmacotherapy for T2D.
1. 2 Chronic complications and difficult problems for pharmacotherapy 
Since the lives of diabetes patients have been greatly extended by insulin 
therapy, clinical physicians now observe chronic complications more frequently, 
including disorders of retina, kidney, nervous system, heart, etc. These are still 
difficult problems for clinicians to treat, even today. Although many types of drugs 
(metformin, sulfonylureas, alpha-glucosidase inhibitors, thiazolidinediones, etc.) 
have been developed since the 1950s, the effects of anti-diabetic treatments are 
always disappointing to some extent. If we compare T2D with infectious diseases, 
we see that most of those diseases have been solved by antibiotics, whereas if 
we compare T2D with hypothyroidism, a fairly similar endocrine disorder with 
insufficient hormone production, we have to admire that those patients can live 
normal lives by simply taking a tablet once a day. Although we can control 
the blood glucose levels so that they are similar to normal and the chronic 
microvascular complications can be delayed, the macrovascular complications, 
which were implicated by UKPDS5, do not seem to be improved. The consoling 
conclusion is that metformin is effective in delaying the process of chronic 
complications6. Hence, although we can do something towards preventing chronic 
complications, the effect is still far from satisfactory.
1. 3 New drugs with different mechanisms
It was hoped new drugs with different mechanisms would solve the problem 
of chronic and longer term complications. A drug delaying the process of 
chronic complications would be helpful for most T2D patients. Glucagon-like 
peptide-1 (GLP-1) receptor agonists for injection (or oral dipeptidyl peptidase-4 
inhibitor, which can protect GLP-1 from hydrolysis) and type 2 sodium glucose 
co-transporters (SGLT2) are two new types of anti-diabetic drugs with new 
mechanisms (Box 1). The former is based on the function of gastrointestinal 
hormones, while the latter stimulates urinary excretion of glucose7. However, 
nobody knows yet whether they will be able to stop the natural progression of T2D.
1. 4 Potential drug targets from genetic research
New technology has made the genetics of diabetes a rapidly progressing 
field8. Completion of the Human Genome Project was the landmark leading to 
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the start of the genetic era in diabetes research. Genome-wide association studies 
(GWAS) of T2D have now discovered approximately 50 loci related to T2D. 
The genes contained in these loci will be potential targets of future anti-diabetic 
drugs, whatever the genes or their products. And these loci have yielded a lot of 
information that implicates otherwise unknown mechanisms of T2D, which will 
lead to a deeper understanding of this complex disease. Furthermore, since GWAS 
of other metabolic traits have also produced many candidate loci, it has become 
feasible to investigate the function of gene interactions in multiple traits. Chapter 
2 introduces the progress made by GWAS in T2D. This chapter reports one 
remarkable finding: that most genes associated with T2D are likely associated with 
beta-cell function instead of IR. If this really proves to be true, then the genetics of 
IR have remained rather less well-defined. Genes associated with other metabolic 
traits, such as dyslipidemia, are potential candidates to relate to IR, and could 
provide important targets for T2D therapy.
Since insulin was discovered, the pharmacotherapy of T2D has made much 
progress. However, we still cannot prevent the chronic complications that result 
from diabetes, although we now have many types of drugs to use in treating T2D. 
New drugs with different mechanisms are being designed and it is hoped they will 
be more effective than the current drugs. Recent progress in genetics is enabling the 
search for new genes in diabetes, which should yield new potential drug targets.
2. Demands of prevention of T2D and the future breach
Since we cannot satisfactorily stop the diabetic processes that initiate chronic 
complications and given the rising prevalence of T2D, the prevention of this disease 
in high-risk groups has become a crucial issue. Pre-diabetes, which is now defined 
as including impaired glucose tolerance (IGT, plasma glucose after glucose load 
in 75g-OGTT is less than 11.1 mmol/L but not less than 7.8 mmol/L) or impaired 
fasting glucose (IFG, fasting plasma glucose is > 5.6 mmol/L but < 7.0 mmol/L), 
is believed to confer a high risk of developing T2D9. So several population-based 
studies in individuals of pre-diabetes were performed10-15. 
2.1 Brief history of diabetes prevention studies in pre-diabetes 
populations
Since pre-diabetes was defined in 2006, most of the intervention studies have 
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been performed in IGT populations. Lifestyle intervention was observed to prevent 
the development of T2D in IGT individuals in 1980 in Malmöhus, Sweden10. The 
later population-based study in Sweden, the Malmö study11, drew the conclusion 
that the incidence of T2D was much lower in the lifestyle intervention group than 
in the reference group at the end of the 5-year study period, although it was not 
a true randomized study. After that, four landmark diabetes prevention studies 
were performed in China (Da Qing IGT and Diabetes study)12, Finland (Diabetes 
Prevention Study, DPS)13, United States (Diabetes Prevention Program, DPP)14 
and India (India Diabetes Prevention Program, IDPP)15. The risk of developing 
T2D was reduced by 42-58% in the lifestyle intervention groups after 3-6 years 
and was seen consistently in all these studies. The US DPP also concluded that 
metformin was effective in preventing T2D. Other pharmacologic interventions, 
such as acarbose16, orlistat17, rosiglitazone and Ramipril18 were tried to test their 
effectiveness in preventing T2D, and most of the conclusions so far have been 
optimistic. 
2.2 Can we intervene earlier?
However, the situation to prevent T2D is still difficult from another viewpoint. 
Although all the outcomes of studies like Da Qing, DPP and DPS proved that 
lifestyle intervention is still effective after the end of the research period, the 
percentage of T2D patients were too high. For instance, in the 20-year follow-
up study of the Da Qing IGT population in China, the prevalence of T2D reached 
93% in the control group and 80% in the lifestyle intervention group19. Such results 
demand that we consider the necessity and possibility of intervening earlier. 
One possible high-risk group that should be identified early are individuals 
with obesity or morbid obesity. The Sweden Obese Subject (SOS) study recently 
gave the results of their 15-year follow-up20, which revealed that bariatric surgery 
can reduce the risk of T2D by 78% in obese individuals. Although bariatric surgery 
is only appropriate for obese patients whose BMI is >35, it is still exciting to see 
that this can be another effective measure to prevent T2D. 
2.3 Will dyslipidemia be a future target of intervention to prevent T2D?
The fact that most T2D patients do not experience a period of severe obesity 
means that bariatric surgery cannot be the mainstream measure of T2D prevention, 
and we should consider other measures and other high-risk candidate groups for 
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T2D. Since dyslipidemia is closely associated with T2D, IR and other glucose-
related traits, is it possible to prevent T2D by intervening in dyslipidemia? The 
key to this problem is whether dyslipidemia is a causal factor of IR or T2D; this is 
discussed in detail in Chapter 3 of this book.
3. Side-effects of insulin and management
The discovery of insulin was a milestone in the history of diabetes therapy, but 
it also provokes side-effects. At the beginning of its clinical application, the two 
main side-effects of insulin were hypoglycemia and insulin allergy. How these side-
effects can best be treated is still a problem, although the situation has become far 
better. 
3.1 Hypoglycemia and a brief history of insulin preparation
Hypoglycemia occurs when the dosage of insulin is more than enough. In 
1922, hypoglycemia occurred frequently in diabetes patients using insulin, because 
the activity of the insulin was different in each batch. Now insulin production is 
standardized but hypoglycemia still exists, although it occurs much less frequently 
and less severely.
The reason that hypoglycemia still exists is that the current model of insulin 
therapy is not ideal. All we can do in insulin therapy is to mimic the physiological 
model of how insulin works in normal individuals, while the physiology is a 
complex system with an automatic negative feedback. When the blood glucose 
increases because of food or other causes, insulin will be secreted into the 
circulation to lower it. When the blood glucose concentration decreases to some 
extent, insulin will stop being secreted. This negative feedback system should 
include a blood glucose sensor, a control center, and an effector to secrete insulin. 
But insulin therapy only mimics the function of the effector. Hence a number of 
preparations and devices have been invented to make the model of insulin therapy 
similar to the most common model of insulin action.
Generally, we can distinguish two parts in the curve of serum insulin 
concentration: basal insulin and food-induced insulin. The former is the amount 
of insulin which is needed for all the physiological actions, and has a low but 
continuous concentration; the latter is the insulin which is needed to treat the 
rapidly increased blood glucose concentration because of calorie intake during 
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a meal, often presented as a peak. To mimic this model of insulin secretion, an 
insulin pump with a speed-modulating device was invented, which is generally 
called continuous subcutaneous insulin infusion (CSII) from the insight of injection 
method. Although it is the best regimen to mimic insulin secretion, its expensive 
price has limited its application. Another solution to mimic insulin secretion is 
the basal-bolus regimen, comprising one daily injection of long-acting insulin 
preparation and three injections of short-acting insulin preparation, one before each 
meal, which demands appropriate insulin preparations. 
However, the insulin introduced in 1922 could only be used as short-acting 
insulin. Furthermore, this short-acting preparation could not perfectly mimic 
meal-induced insulin because it was injected subcutaneously, while the insulin 
secreted by islets was released directly into the portal vein to initiate its function 
immediately. This is the reason why such insulin preparations need to be injected 
20-30 minutes before a meal. Practical basal insulin preparations and better bolus 
insulin preparations were strongly needed. In the following 90 years, more and 
more types of insulin preparations were invented to mimic basal or bolus insulin 
(Box 2). Although none of the current regimens can attain the level of a negative 
feedback system, hypoglycemia occurs less than before for the same extent of 
blood glucose control.
Box 2 Brief history of development of insulin preparations
1922 Insulin was first used in clinical medicine
1936 Zinc or protamine was found to be able to prolong the action time of insulin
1946 The commonest intermediate-acting insulin preparation, NPH, was invented
1973 Highly purified insulin preparation was invented
1982 Recombinant human insulin preparation was invented
1994 Rapid-acting insulin analogue Lispro was invented
1995 Rapid-acting insulin analogue Aspart was invented
2000 Long-acting insulin analogue Glargine was invented
2000 Long-acting insulin analogue Detemir was invented
2004 Rapid-acting insulin analogue Glulisine was invented
2011 Long-acting insulin analogue Degludec was invented
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3.2 Brief history of insulin allergy 
Besides hypoglycemia, another main side effect of insulin when it was 
introduced in 1922 was allergy21. Nearly every patient accepting insulin therapy 
suffered from local skin symptoms due to insulin allergy. The main causes 
of insulin allergy are the impurity and animal origin of insulin preparations. 
Most of those patients suffered from IgE-mediated allergy, also called type I 
hypersensitivity, and desensitization therapy was invented to alleviate this problem, 
but the effect was only partly valid. The principle of desensitization was to induce 
immune-tolerance, but it was not always successful. However, this problem was 
solved satisfactorily with the development of later pharmaceutical drugs. The 
appearance of highly purified insulin preparations solved the problem of impurity, 
while the recombinant technique solved the problem of the animal origin. In the 
early 1980s it was believed that insulin allergy in humans had been conquered. 
However, insulin allergy still occurs after the use of recombinant insulin 
preparations in spite of having a low prevalence nowadays; unfortunately it seems 
more difficult to treat. Human-insulin-specific IgE was identified in the sera of 
these patients and all we can offer is the unsatisfactory desensitization therapy. 
Fortunately, two technical advances improved the embarrassing situation 
of insulin allergy treatment. One was the appearance of various types of insulin 
analogues, and the other was the popularization of CSII22. Rapid-acting insulin 
analogues seem to decrease the antigenicity through avoiding formulation of 
hexomers, while long-acting insulin analogues seem to hide the epitopes of insulin 
preparations. Although CSII was used to treat insulin allergy as early as 1987, it 
was seldom used for this rare disorder until the 21st century, because CSII is now 
much more convenient and cheaper. It can provide enough insulin for a diabetic 
patient at a very slow infusion rate, which avoids attaining the dosage to induce 
allergy. Clinical application of insulin analogues and CSII mean we can now treat 
patients with insulin allergy much more effectively. 
Generally speaking, insulin analogues and CSII are helpful for diabetic 
patients with insulin allergy. However, CSII should be used lifelong by these 
patients, which is often impossible to achieve in many developing countries. Is 
it possible to use CSII only for desensitization instead of as a long-term therapy 
regimen? Chapter 4 describes the effort to manage this regimen.
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3.3 Insulin antibody and dysglycemia
In the early period of insulin therapy, hypoglycemia and allergy were very 
common. And another strange situation also occurred spasmodically: larger and 
larger insulin dosages were needed to acquire glycemic control even though 
the patient was not very obese. This was later proved to be due to another type 
of allergy, type III hypersensitivity induced by insulin. The pathophysiological 
mechanism is that insulin antibody (IgG) induced by insulin preparation binds 
insulin to formulate an antigen-antibody complex, so that the circulating isolated 
insulin is not sufficient to maintain normal glucose concentrations. Similar to 
typical type I allergy, this disorder of the antigen-antibody complex has become 
much rarer since recombinant insulin preparations were introduced. However, there 
are occasionally reports about similar situations induced by IgG, which is needed to 
treat patients with glucocorticoid, specific immunosuppressants, or plasmapheresis. 
This rare disease was classified as one subtype of severe insulin resistance 
syndrome.
Another extreme type of insulin antibody-induced disorder is hypoglycemia. 
In 1970, Hirata et al reported the first patients with insulin-autoimmune syndrome 
(IAS)23. After that, several hundreds of these patients were reported. The 
pathophysiological mechanism is also due to the circulating antigen-antibody 
complex. Insulin antibody – induced by some drugs with sulfhydryl compounds 
– binds endogenous insulin to form antigen-antibody complex, but this kind of 
complex can spontaneously dissolve into isolated insulin and antibody, which can 
induce severe hypoglycemic attacks. Although it has been defined that a patient, 
without using insulin, could be considered as diagnosed with this disease, some 
patients treated with insulin rather than with drugs with sulfhydryl compounds have 
also been classified as having insulin autoimmune syndrome. Most IAS patients 
had a spontaneous remission after the sulfhydryl compounds were discontinued, 
but for those patients whose attack was induced by insulin, glucocorticoid therapy 
was always necessary. 
Insulin-induced antigen-antibody complex can cause disorders of dysglycemia. 
In Chapter 5, we describe one case of hypoglycemia with pseudo-negative insulin 
antibody and one case of hyperglycemia with a zero serum insulin concentration, 
and we propose a novel classification of dysglycemia induced by insulin-related 
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antigen-antibody.
4. T2D: the more we know, the more we realize how much 
we don’t know
In the past 100 years, seven Nobel prizes have been awarded in total for 
contributions to diabetes1 since Banting and Macleod won their Nobel prizes 
in 1923 for the discovery of insulin, but theirs was the only one that was an 
achievement in therapy. Although we have found several new effective drugs, none 
of them can attain the achievement of insulin at that time. This means that we do 
not have sufficient knowledge to make influential progress now, and we should do 
more research on the mechanisms of diabetes. 
In the past five years, GWAS-related research has provided much more 
information. But the most different characteristic of this research is that we have 
not understood most of the information we acquired. It is really a big challenge 
for scientists to “decode” this information into understandable knowledge. Hence 
this situation confronts us with more surprises and confusion than before, which 
not only always makes us feel ignorant but provides us with more opportunities 
to better understand diabetes. It therefore seems that the next Nobel prize for 
diabetes will still be awarded for work on the disease mechanisms rather than new 
treatments.
Another trend in the post-genomic era is the development of other “omics” 
research, including transcriptomics, proteomics, metabolomics, lipidomics, etc. 
These “omics” research techniques can be applied to nearly every type of body fluid 
(plasma, urine, saliva, etc.) and/or tissue (adipose, liver, muscle, etc). Furthermore, 
as genomics develops, epigenomics appears to give us more information about 
environmental influences on genes. The emergence of more and more data to be 
“decoded” seems to have become normal. Preliminary studies of these new subjects 
have tried to search for biomarkers for the early diagnosis, chronic complications, 
and management of diabetes. 
In the current situation, it is more and more important to focus on systems 
biology24. Although “systems” science dates back to Cybernetics by Norbert Wiener 
in the 1940s and General Systems theory by Ludwig von Bertalanffy in the 1950s, 
it was neglected for many years until the information produced by GWAS-related 
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research. How we can best use all the different kinds of “omics” data to understand 
the etiology of a disease is one of today’s urgent demands, and the goal of systems 
biology.
Lipid metabolism is also important for human beings, and 14 Nobel prizes 
have been awarded for related research. Lipid metabolism is closely associated 
with glucose metabolism, and dyslipidemia is a possible causal factor of insulin 
resistance, as we describe in Chapter 3. Hence, it is naturally being speculated 
that the combined effects of lipid genes may influence glucose-related traits. Since 
GWAS-related research provides us with so much data about lipid genes, we can 
use polygenetic models from insights offered by systems biology to investigate 
their possible relationship.
In Chapter 6, we describe our investigation into the relationship between 
lipid genes and glucose-related traits. An insufficient number of genes related to IR 
and the close association between lipids and glucose-related traits seem to imply 
there is an internal relationship hidden behind some complex traits. We used the 
information GWAS have provided about lipids, but surprisingly found the opposite 
pleiotropic effects of lipid genes on glucose-related traits. We set out to determine 
the relationship between lipid genes and glucose-related traits – and we succeeded 
– but the unexpected answer shows that many more questions are waiting for us.
5. Summary
Since insulin was first used in clinical medicine, the clinical management of 
diabetes has been revolutionized. Accompanied by the longer lifespan of diabetic 
patients, we recognized that diabetes is a much more complex disease than had 
been expected. But what reveals our ignorance can also inspire us to make more 
progress, not only in clinical therapy, such as improving the desensitization of 
insulin allergy, but also in the disease mechanisms, such as the causal relationship 
between dyslipidemia and IR. Our understanding of diabetes is much deeper than 
before, especially since the start of the era of genetic studies. The pleiotropic 
effect of lipid genes on glucose-related traits that is presented in this book is not 
just a simple reply to the question we asked, but also a new and important topic 
composed of several questions.
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CHAPTER 2
Genetic insights through 
genome wide association studies 
in type 2 diabetes mellitus will 
lead to new therapeutics
Marcel G. M. Wolfs*, Naishi Li*, Jingyuan Fu, 
Cisca Wijmenga, Timon W. van Haeften, Marten H. Hofker$
Chapter 9 in Advances in Genome Science (Volume 1): Changing Views on Living 
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Abstract: Type 2 diabetes is a disorder of dysregulated glucose homeostasis. Normal glucose 
homeostasis is a complex process involving several interacting mechanisms, such as insulin secretion, 
insulin sensitivity, glucose production, and glucose uptake. The dysregulation of one or more of these 
mechanisms due to environmental and/or genetic factors, can lead to a defective glucose homeostasis. 
Hyperglycemia is managed by augmenting insulin secretion and/or interaction with hepatic glucose 
production, as well as by decreasing dietary caloric intake and raising glucose metabolism through 
exercise. Although these interventions can delay disease progression and correct blood glucose levels, 
they are not able to cure the disease or stop its progression entirely. Better management of type 2 
diabetes is sorely needed. Advances in genotyping techniques and the availability of large patient 
cohorts have made it possible to identify common genetic variants associated with type 2 diabetes 
through genome-wide association studies (GWAS). So far, genetic variants on 50 loci have been 
identified. Most of these loci contain or lie close to genes that were not previously linked to diabetes 
and they may thus harbor targets for new drugs. It is also hoped that further genetic studies will pave 
the way for predictive genetic screening. The newly discovered candidate genes for type 2 diabetes 
can be classified based on their presumed molecular function, and we discuss the relation between 
these gene classes and current treatments. We go on to consider whether the new genes provide 
opportunities for developing alternative drug therapies. 
Key words: type 2 diabetes, drug targets, genetics, personalized medicine.
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INTRODUCTION
The last few decades have witnessed a dramatic increase in the prevalence of 
type 2 diabetes mellitus, due to changes in food intake combined with less physical 
exercise, a lifestyle often referred to as Western. The long-term consequences 
of type 2 diabetes are severe and include cardiovascular disease, retinopathy, 
neuropathy, nephropathy, and diabetic foot disease. While it has been estimated 
that worldwide around one billion people are obese, over 180 million people suffer 
from type 2 diabetes and this number is expected to double over the next 25 years. 
The number of annual deaths due to type 2 diabetes is difficult to estimate because 
they are often hidden under cardiovascular disease, but the WHO has estimated it 
to be between 1 and 3 million in 2006. However, since mortality from this disease 
often occurs many years after its onset, even 3 million deaths is probably an 
underestimate of the death toll in the near future. Although external factors such as 
food-intake-related obesity have attracted much attention, the genetic predisposition 
for diabetes is also important. While the life-time risk for type 2 diabetes in the 
Western world is around 10%, first-degree relatives of patients have a 20–40% risk 
for the disease, and concordance rates for identical twins have been estimated to 
be 57% or higher (up to 90%) for type 2 diabetes in male twins1. The endeavor 
to find the underlying genes was unsuccessful for many years although hundreds 
of genetic associations have been described, based largely on candidate genes. 
Unfortunately, replication was only possible for a very few variants. However, the 
recent advent of genome-wide association studies (GWAS) holds promise, since 
such studies have now uncovered a number of common genetic variants related to 
diabetes for which replication is also possible. These genes had not previously been 
linked to diabetes and these loci are therefore expected to lead to new insights into 
the disease mechanisms.
GLUCOSE HOMEOSTASIS AND DIABETES
Diabetes is a state of persistent hyperglycemia, leading to irreversible damage 
in a number of tissues, especially the retina, the kidney glomeruli, neural tissue 
and blood vessels. Normally plasma glucose levels are kept within a narrow range, 
a process referred to as glucose homeostasis. This homeostasis is regulated in a 
complex way and involves several axes. 
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After eating a meal, a person’s plasma glucose rises temporarily, after which 
glucose is rapidly taken up by liver and muscle and to a lesser degree by fat 
tissue, due to the effects of insulin released from the pancreatic β-cells. Under 
these circumstances, glucose is converted into glycogen, which is then stored in 
the liver. When plasma glucose levels have dropped, insulin secretion gradually 
diminishes. In the post-prandial state, a minimum level of plasma glucose is 
assured by glucose production in the liver, partly due to release from glycogen and 
partly due to new formation from precursors such as lactate and the amino acids 
alanine and glutamine. Insulin has a number of other effects, including lipid storage 
in adipocytes, and it even increases DNA replication and protein synthesis. The 
regulation of insulin release is complex; apart from the prevailing plasma glucose 
level, release from various peptides from the intestine (e.g., glucagon-like peptide 1, 
GLP1) after a meal and feedback mechanisms ensure adequate insulin release. 
Type 2 diabetes is characterized by the combination of disturbances in insulin 
secretion, and an impairment of the effects of insulin, so-called insulin resistance, 
which is often related to obesity. Insulin resistance is caused by defects in the 
signaling pathways that process the insulin signal in its target tissues. It has often 
been stated that the disease starts with insulin resistance accompanied by raised 
insulin and glucose levels. At a later stage, we presume β-cells undergo further 
damage and apoptosis, and are not able to keep up with the demand for insulin 
release, which then results in higher glucose levels. At least one of the pathways 
involved in insulin secretion, β-cell regeneration, β-cell survival, or β-cell 
development are important in determining the vulnerability of the β-cell pool in 
insulin-resistant conditions. Studies have shown decreases in β-cell function prior 
to the augmentation of plasma glucose in normal glucose-tolerant first-degree 
relatives of type 2 diabetes subjects; in these studies these relatives had normal 
insulin sensitivity2,3. While obesity is a major risk factor for diabetes – around 50% 
of obese subjects will develop type 2 diabetes at some stage (depending on the age 
when they became obesity), it should be noted that 20% of type 2 diabetes subjects 
are not obese. It thus seems that obesity is a major risk factor for developing type 2 
diabetes, but that it is the vulnerability of the β-cell pool which determines whether 
obesity in fact triggers type 2 diabetes.
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Although monogenic forms of diabetes have been found (Table 1) (reviewed 
in4), the majority of cases of type 2 diabetes do not show inheritance as a 
Mendelian trait, but rather as a genetically complex disorder in which genetic 
variants predispose individuals to develop the disease. Twin studies have revealed 
concordance rates of over 50 % (and reported up to 90%) for type 2 diabetes in 
identical twins1, which still leaves a substantial role for environmental factors, such 
as excess food and limited physical activity. The rapid rise in diabetes prevalence 
over the last few decades strongly suggests that genetic variants involved in type 2 
diabetes are interacting with environmental factors. 
Candidate-based association studies 
Several candidate gene association studies have been performed to identify 
genes involved in type 2 diabetes. These studies test some of the genetic variants in 
a gene that is a strong candidate for being involved in the disease. Although a few 
genes have been identified in this way, in general these studies have not been very 
successful because the results could not be replicated and the p-values for association 
of the genetic variants were moderate. 
Obviously, the few diabetes genes that were identified and replicated in 
candidate-based association studies had already been linked to a diabetic phenotype, 
since the tested genes were mainly selected on the basis of their function and 
their potential relationship with diabetes. The genes identified by candidate gene 
approaches were found to be involved in rare, monogenic forms of diabetes. The 
TCF2 gene was linked to maturity-onset diabetes of the young (MODY) 55, while 
WFS1 gene mutations led to Wolfram (or DIDMOAD) syndrome, a rare, lethal, 
neurodegenerative disorder that includes diabetes insipidus, diabetes mellitus, 
optic nerve degeneration, and inner ear deafness6. The KCNJ11 gene is related to 
permanent neonatal diabetes mellitus (PNDM), a rare form of diabetes starting 
before the age of 6 months7. Finally, mutations in PPARγ can lead to insulin 
resistance, hypertension, and lipodystrophy8. Although the molecular impact of 
mutations in these genes is not yet fully understood, it is likely that mutations in 
them will have differing effects and that mutations involved in type 2 diabetes 
will have a milder impact on human physiology than those involved in monogenic 
diabetes.
Novel Mechanisms for Prevention and Treatment of Type 2 Diabetes26
Genome-wide association studies (GWAS)
Recent advances in genotyping techniques and the collection of large, type 
2 diabetes patient cohorts have made it possible to perform hypothesis-free 
genome-wide association studies (GWAS) to identify common genetic variants 
that increase susceptibility to type 2 diabetes. The human genome harbors around 
3 billion base-pairs, which contain at least 3 million common single nucleotide 
polymorphisms (SNPs) according to the International HapMap Project. However, 
alleles represented by SNPs that are close together have often stayed on the 
same chromosome in further generations, forming a so-called haplotype. This 
implies that when one variant has been typed, we know the genotype of a set of 
other variants that surround the initial genetic marker; in genetic terminology it 
is said that the SNPs that stayed together on a chromosome are in high linkage 
disequilibrium. It has been estimated that, in a Caucasian population, assessing 
500,000 SNPs will detect around 80% of the common genetic variation. GWAS 
typically involve the assessment of such numbers of SNPs determined in large 
case-control studies for association with a disease or with a so-called “phenotypic 
trait”, i.e., type 2 diabetes. It should be noted that GWAS identify association of a 
genetic locus, and not directly of a gene. It is likely that the most associated SNPs 
in a genomic region are not the causal variant, but that the disease-producing SNP 
is in high linkage disequilibrium with the “associated” SNPs. It is also possible 
that a SNP, even when located in a gene, can influence the expression of a nearby 
gene located several thousand base-pairs or more away9. It is therefore difficult to 
determine which gene is responsible for the association signal in a GWAS with full 
certainty. A detailed description of a GWAS is reviewed by McCarthy et al10. 
The genome-wide approach has been very successful for type 2 diabetes, 
leading to the identification of quite a few common genetic variants associated with 
the disease lying near genes that had not previously been associated with a diabetic 
phenotype (Table 1)11-38. In the near future this number will probably further 
increase and a large part of the genetic variation that confers susceptibility to type 
2 diabetes will be unveiled. At present, the total effect of the identified genetic 
variants only explains 10 to 15% of the total type 2 diabetes heritability39-41. This 
small explained percentage of the total type 2 diabetes heritability indicates that the 
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largest proportion of genetic variation involved in type 2 diabetes still await their 
discovery. Unveiling this so-called missing heritability42,43 likely will lead to more 
interesting discoveries about genetics of type 2 diabetes.
Functions of candidate genes for type 2 diabetes 
As discussed above, type 2 diabetes is a disease characterized by impaired 
β-cell secretion of insulin, in combination with resistance to insulin in its target 
tissues. Both insulin secretion and insulin sensitivity are influenced by genetic and 
environmental factors44. Genes that harbor variants associated with diabetes can 
thus be expected to exert their effect through one of these pathways. 
Most genes that play a role in monogenic diabetes are important for pancreatic 
β-cell growth and/or function (Table 1). Genetic variants in three (KCNJ11, TCF2, 
WFS1) out of four replicated genes for type 2 diabetes found by candidate-based 
genetic association studies are also related to decreased β-cell function. The best 
characterized gene is KCNJ11 which encodes a member of a β-cell potassium 
channel involved in insulin secretion45. Mutations in TCF2 are associated with 
insulin secretion46, while knock-out mutations in WFS1 have been found to lead to 
Endoplasmic Reticulum (ER) stress and subsequent apoptosis of pancreatic β-cells47. 
The protein product of the fourth gene identified by a candidate gene approach, 
PPARγ, is involved in adipocyte differentiation and function (reviewed in48). Since 
rare mutations in this gene lead to insulin resistance and lipodystrophy, variations 
in this gene are likely to contribute to type 2 diabetes susceptibility through altered 
insulin effects in adipose tissue.
To explore the functions of the newly discovered genes, various studies 
have investigated their roles in determining sub-phenotypes of type 2 diabetes, 
such as peripheral insulin sensitivity and β-cell insulin secretion, and the genetic 
variants identified in GWAS (except KCNQ1 because variants in this gene have 
only recently been identified)15,49-88. In general, these studies indicate that the 
genetic variants in the genes identified by association studies mainly act through 
interference with insulin secretion instead of peripheral insulin sensitivity, and 
are thus similar to the genes identified through candidate gene approaches and in 
monogenic diabetes. However, insulin secretion and insulin sensitivity are related 
through complex and poorly understood mechanisms. Expression studies have 
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revealed that most of the newly discovered candidate genes for type 2 diabetes are 
expressed in multiple cell types throughout the body and that the expression of 
some of these genes under diabetic conditions is unaltered in the pancreatic islets 
whereas it is different in other tissues (reviewed in 89). Functional studies of the 
molecular mechanisms by which most genetic variants lead to impaired insulin 
secretion and the use of animal models have been quite limited but are sorely 
needed90. 
In the past five years, GWASs have led to the discovery of 50 new candidate 
genes related to type 2 diabetes. However, it is still possible that there are mutations 
in genes that affect other axes of the underlying mechanisms of diabetes. It has 
been proposed that multiple hits in several diabetes pathways generally occur 
in subjects destined to develop type 2 diabetes. Some genes related to insulin 
resistance have been found by GWAS, although the number of genes related to β-cell 
failure is much larger. Thus, genetic variation associated with type 2 diabetes seems 
to be more prominently involved in β-cell failure than in insulin resistance. 
Genetic subgroups
1.  Genes related to β-cell failure
It can be proposed that some of the candidate genes for type 2 diabetes related 
to β-cell failure can be grouped into four subgroups based on what is known about 
their molecular function, see Fig. (1) (Some candidate genes are not included in 
this figure because their functional relation to diabetes is totally elusive). First, 
KCNJ11, KCNQ1, ABCC8, KCNK16 , SLC30A8, SRR, ADAMTS9, MTNR1B, 
CAMK1D, CENTD2, DUSP9,BCL11A, PRC1 and CHCHD9 gene products are 
probably involved in cellular ion homeostasis and insulin secretion. A second group 
of genes – TCF7L2, TCF1, TCF2, HHEX / IDE, IGF2BP2, CDKAL1, GLIS3,and 
NOTCH2 –is likely to be involved in the growth and development of the pancreas, 
which likely influences the overall capacity of the pancreas to secrete insulin. Of 
this group TCF7L2, TCF1, and TCF2 are important in Wnt signaling (reviewed 
in literature91). In line with the presence of this group of type 2 diabetes candidate 
genes, some genes whose deficiency can induce MODY, such as NEUROD1, 
PDX1, HNF4A, and PAX4, are also related to pancreas growth and development. 
A third group is related with cell cycle events: JAZF1 and TCF2 have both been 
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associated with prostate cancer and these genes might play a role in the regulation 
of the cell cycle92-94. CDKN2A, TP53INP1, and CDC123 also play a role in the cell 
cycle. Finally, THADA and WFS1 are thought to be involved in the apoptosis of 
β-cells. Genes involved in the cell cycle and apoptosis of β-cells might play a role 
in diabetes by dysregulating the response of β-cells when a higher insulin output is 
called for when insulin resistance is present.
2.  Genes related to insulin resistance
Several genes associated to type 2 diabetes in GWAS seem to be related to 
insulin resistance, which can be classified into four subgroups.  First, FTO, can be 
classified as a separate group amongst the type 2 diabetes candidate genes since it 
is the only gene that is associated with both obesity and type 2 diabetes95,96. In line 
with this, Fto deficient mice (Fto-/-) have a significant reductionin adipose tissue 
and lean body mass. Thus, the association between FTO and type 2 diabetes might 
be driven by obesity. PPARG may be the only member of the second subgroup, 
Fig. (1). Classification of candidate genes for type 2 diabetes with a potential role in β-cell function.
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which is believed to influence insulin sensitivity by affecting both adiposity and 
post-receptor pathway of insulin.  A third group includes IRS1, GRB14, PTPRD, 
DUSP9 and SPRY2, are closely associated with the insulin receptor signaling 
pathway, and are thought to be related to type 2 diabetes by this mechanism. 
For example, the protein product encoded by IRS1 is phosphorylated by insulin 
receptor tyrosine kinase directly. Finally, KLF14, ADAMTS9 and HMGA2 may be 
also related to insulin resistance 27; however, knowledge about their mechanism is 
still limited.
MANAGEMENT OF TYPE 2 DIABETES AND HOW IT 
IS RELATED TO GENETICS
The corner stone for diabetes management still lies in diet and exercise97,98. 
There is also a slowly expanding list of drugs being used to treat type 2 diabetes, all 
of which act through one of the pathways important in diabetes pathophysiology. 
Fig. (2). Classification of candidate genes for type 2 diabetes with a potential role in insulin 
resistance.
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However, neither changes in lifestyle nor the use of medication are sufficient to 
cure diabetes, although both interventions can delay the progression of disease. 
There is therefore an urgent need to develop new medications or strategies to 
counter the huge increase in cases expected in the future. Since the management of 
type 2 diabetes with either lifestyle changes, medication or both, is more effective 
when started at an early stage, improving the techniques for early diagnosis and the 
opportunities for early intervention will greatly improve the effects of current ways 
of managing type 2 diabetes.
Pathways important for the function, growth and development of pancreatic 
β-cells provide obvious drug targets and are already being used, since defects 
in insulin secretion play a central role in diabetes. Sulfonylurea derivatives are 
widely used and act through improving β-cell function by closing β-cell potassium 
channels and thereby enhancing insulin secretion. Some of the genes associated 
with both monogenic (ABCC8 and KCNJ11) and complex diabetes (KCNJ11, 
KCNQ1) encode subunits of these potassium channels and accordingly, monogenic 
diabetes of this type can be well managed with sulfonylureas. SLC30A8 encodes a 
zinc transporter protein in the β-cell and the function of this gene product might be 
related to that of the potassium channel genes by regulating ion homeostasis in the 
β-cell99.
The actions of various other drugs involve provoking different effects rather 
than augmenting insulin secretory function: thiazolidinediones enhance insulin 
activity by acting on adipose tissue, metformin lowers hepatic glucose output, 
α-glucosidase inhibitors delay digestion and absorption of intestinal carbohydrate, 
sodium-glucose cotransporter 2 inhibitors increase urinary glucose excretion 
and pramlintidine delays gastric emptying and inhibits the release of glucagons. 
GLP1 receptor-agonists or DPP-4 inhibitors have combined actions on food 
intake by regulating satiety and enhancing insulin secretion in the short term, 
and β-cell neogenesis and proliferation in the long term (reviewed in 100). The 
exact physiological mechanisms that underlie these improvements are, however, 
unclear. Except for PPARγ and genes involved in pancreas growth and survival, 
there is no evidence that any of the other genes identified by GWAS are involved 
in any of these processes. The protein product of PPARγ is likely to be involved 
in the mechanism targeted by thiazolidinediones because these compounds are 
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ligands of PPARγ receptors in spite that physiological ligand has not been found101. 
Metformin, the only representative of biguanides, is now believed to be the most 
widely prescribed oral antidiabetic drug in the world, but its mechanism is too 
complex to be completely understood. There is some evidence that PPARγ can 
inhibit hepatic glucose production through the AMPK pathway102. However recent 
research showed that metformin was equally effective to the AMPK deficient mice 
(AMPK-/-) as to wild type mice, which suggests that metformin could reduce 
hepatic glucose production through AMPK-independent pathways103,104. Although it 
seems likely that some of the newly discovered candidate genes for type 2 diabetes 
act in a pathway that is targeted by GLP1 receptor-agonists or DPP-4 inhibitors, 
more research into both the mechanisms of the medication and the function of the 
genes is needed.
I M P L I C AT I O N S  F O R  P R E V E N T I O N  A N D 
TREATMENT
Genetic screening for prediction and prevention
The effectiveness of current type 2 diabetes management is greatly improved 
when it is started at an early stage of the disease. If genetic testing could be used 
to predict type 2 diabetes, preventive measures could be taken and diabetes could 
potentially be managed more easily. However, the variants associated with type 2 
diabetes that have been identified so far only explain a small percentage of the total 
genetic variation that is thought to be present39-41. It is therefore not yet possible to 
perform accurate predictive genetic testing but, in the near future, research should 
provide more insight into the opportunities for such testing. Firstly, it is expected 
that many more common genetic variants will be identified by performing GWAS 
in other populations and by improving their power and genomic coverage (i.e., 
more patients included in studies and more SNPs tested). Secondly, performing 
thorough analyses of the genomic regions that show association to the disease by 
resequencing large numbers of patients and controls may identify genetic variants 
that have higher odds ratios than the common genetic variants identified so far. In a 
GWAS it is unlikely that the functional variant will be identified, but rather one or 
more common variants to which the disease variant is in linkage disequilibrium, i.e., 
that the actual causative mutation(s) is in close vicinity to the tested variant. If the 
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frequency of the causal disease variant is lower than the tested common SNP, we 
can expect the odds ratio of the causal SNP to be higher and this would make the 
causal SNP a better candidate to use for genetic testing. One drawback of genetic 
testing is that many variants have to be tested for each subject, which is laborious 
and costly at present, but improved genotyping and resequencing technologies will 
make screening for such variants feasible in the near future. 
New opportunities for intervention
Even if the exact functions of the majority of the genes associated with type 2 
diabetes are still elusive, they can be broadly grouped into several classes, see Fig. 
(1) and Fig. (2). When certain genes are involved in the same molecular pathway or 
physiological process, not only these genes but the entire pathway or process would 
be an obvious target for new anti-diabetes drugs. In combination with genetic 
screening, such information could be used to optimize diabetes management by 
prescribing drugs that act on those pathways that are affected in a patient, and vice 
versa, it is also possible that altering the activity, be it stimulation or inhibition, 
of undisturbed processes could improve glucose homeostasis in selected patients. 
Improved drug treatment in diabetes can be seen in the current management of 
various MODY subtypes. As described above, mutations in genes involved in 
β-cell signaling and/or growth in the pancreas have been found to be responsible 
for MODY subtypes. After these mutations were identified, the management of 
these diseases was greatly improved by the use of sulfonylurea derivatives, which 
enhances insulin secretion instead of exogenous insulin99. The good response of 
MODY3 patients to sulfonylurea treatment serves as an excellent example of 
personalized therapy based on genetic screening. 
Evidence that genes identified by GWAS can represent targets for managing type 
2 diabetes is provided by the association to this disease of variants in the KCNQ1 
and KCNJ11 genes. Both these genes encode proteins that are members of β-cell 
potassium channels important for insulin secretion and these channels are targeted by 
sulfonylurea derivates which are already widely used anti-diabetic drugs 99. 
Another gene, found through a candidate-based association study and likely to 
act in the pathway targeted by thiazolidinediones, is PPARγ. On the physiological 
level no relationships are known between current medications and all the other 
genetic variants identified in either GWAS or candidate gene association studies. 
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Therefore all these genes represent new potential targets for intervention. 
However, most of the candidate genes for type 2 diabetes have not yet been 
studied well enough to predict whether interference with their products could be 
used in managing diabetes. Studies are needed in order to better classify these 
genes. 
Common variants in candidate genes for type 2 diabetes relating to cell cycle 
events and apoptosis, and representing different alleles than those associated to 
type 2 diabetes, are also associated with various cancers. In addition, the risks of 
developing diabetes and prostate cancer are correlated in a complex way: overall 
diabetes risk and prostate cancer risk are inversely correlated, but while diabetes 
risk and the risk of developing aggressive prostate cancer show no correlation, these 
two risks are positively correlated in lean men and in men who undertake vigorous 
physical activity105. Systemic administration of agents interfering with the gene 
products of diabetes genes that are also associated with cancers could, therefore, be 
beneficial in treating diabetes, but they might be potentially carcinogenic. Tissue-
specific drug targeting or additive medication to overcome the carcinogenic side-
effects of such medication needs to be developed to overcome this problem. Hence, 
cell-cycle related genes are probably not the most promising targets for developing 
new diabetes treatments, unless cell-type-specific targeting of drugs becomes a 
reality.
Although the genes containing variants associated with type 2 diabetes that 
seem to be involved in pancreatic growth and development have not been well 
studied yet, we can speculate on several possibilities for intervention with such 
genes. Because most genes in this category are not associated with other diseases, 
they represent promising intervention targets. Variants in these genes might affect 
the regenerative or proliferative potential of the β-cell population when there is an 
increased demand for insulin secretion. In this case it would be possible to use such 
genes, or the molecular pathways they are involved in, as a target for intervention, 
in an attempt to correct the poor response of the β-cells and ultimately aiming to 
improve insulin secretion. 
Another possibility is that variants in these genes cause pancreatic damage, 
which would lead to endocrine malfunction of the pancreas at an early stage of the 
diabetic development. The possibilities for therapeutic intervention would largely 
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depend on the severity and reversibility of such a malfunction. 
Genetic variants in three genes identified (or confirmed) by GWAS (TCF7L2, 
CDKAL1, and SLC30A8) are associated with impairment of proinsulin-to-insulin 
conversion, whereas variants in other genes identified by GWAS are not associated 
to this106. Even if the affected proinsulin-to-insulin conversion is not a primary 
but a secondary effect of genetic variants in one of the three genes, reconstituting 
this process would enhance insulin secretion and thereby enhance β-cell function. 
Although the conversion of proinsulin-to-insulin has long been known to be 
involved in type 2 diabetes107, the mechanisms that regulate this process are still 
undetermined and there is no current therapy that acts by interfering with this 
process. Association of TCF7L2, CDKAL1, and SLC30A8 to impaired proinsulin-
to-insulin conversion has provided evidence that these genes are somehow related 
to this process and this clears the way for functional research and development of 
new medication. 
CONCLUSIONS
GWAS are an important tool for identifying genetic variation and they 
have been very successful in finding 50 genetic loci involved in type 2 diabetes. 
Genotyping techniques will continue to improve and patient cohorts will become 
larger, which will lead to more genetic variants being identified in the near future. 
Although the true causal SNPs are often not known, it is anticipated they will 
be uncovered by deep sequencing of the genomic regions containing association 
signals. These advances will help elucidate a higher percentage of the total genetic 
variation, and improve opportunities for genetic screening and personalized 
diabetes care. Functional studies and animal models harboring specific gene 
deletions will be needed to study the role of such mutations, while genetic studies 
using sharply defined endophenotypes will greatly enhance our knowledge about 
the candidate genes for type 2 diabetes identified by GWAS. 
At present, it is too early to expect results from GWAS to lead to new 
therapies. Nevertheless, it is clear that genetic studies are crucial to dissecting the 
mechanisms underlying the biological processes and to finding ways to intervene 
with them, as they provide important clues for directing the focus of functional 
research. The ongoing avalanche of genetic information about type 2 diabetes will 
Novel Mechanisms for Prevention and Treatment of Type 2 Diabetes36
thus pave the way to further research in the field and has already yielded important 
information to aid the development of new therapeutic strategies.
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Abstract
Insulin resistance often occurs with dyslipidemia as part of the metabolic syndrome and the 
current dominant paradigm is that insulin resistance leads to dyslipidemia. However, dyslipidemia 
may also cause insulin resistance; this was postulated 30 years ago and has never been refuted. 
This review summarizes recent evidence from epidemiological, genetic and intervention studies to 
readdress this old hypothesis.
In large patient cohorts of diverse genetic origin, high plasma levels of triglyceride and low 
levels of high-density lipoprotein cholesterol (HDL-C) have been shown to predict insulin resistance, 
while the same is also true for common APOC3 and LPL polymorphisms. In addition, genetic 
predisposition to a high triglyceride/low HDL-C, as determined by genome-wide association studies, 
has been related to an elevated risk for type 2 diabetes. It has further been suggested that lipid-
modulating drugs can alleviate insulin resistance. Possible mechanisms as to how dyslipidemia may 
contribute to insulin resistance include lipotoxicity, endoplasmic reticulum stress, and inflammation.
Establishing whether dyslipidemia plays a causal role in the etiology of insulin resistance is 
important since it could reveal new avenues for combating type 2 diabetes.
1. Introduction
1.1 Need for new pharmaceutical targets to prevent type 2 diabetes (T2D)
1.2 Insulin-resistant state as target for preventing T2D
1.3 Dyslipidemia as a possible causal factor of insulin resistance
2. Epidemiological studies 
3. Genetic studies
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4. Intervention studies 
4.1 LDL-C lowering treatments
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4.3 HDL modulating treatments
5. Using systems genetics to understand disease etiology 
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1. Introduction
1.1 Need for new pharmaceutical targets to prevent type 2 diabetes (T2D)
The prevalence of T2D is increasing so rapidly that it has become a serious 
problem worldwide1,2. Since we still have no ideal therapy for T2D or its chronic 
and serious complications, prevention is of the utmost importance. 
This point is clearly illustrated by several large-scale interventional trials in 
Chinese3,4, American5,6 and Finnish populations7,8, which showed that a considerable 
proportion of patients with impaired glucose-tolerance (IGT) still developed T2D 
after several years of follow-up, in spite of apparently effective interventions such 
as lifestyle changes and metformin use. For instance, in the Da Qing Diabetes 
Prevention Outcome Study, 80% of IGT individuals in the lifestyle intervention 
group (diet, or exercise, or diet plus exercise) had developed T2D after 20 years 
of follow-up, although the lifestyle intervention group did much better than the 
controls (in which 93% of IGT individuals suffered from T2D after 20 years)4. 
These findings underscore the urgency to prevent T2D at a much earlier stage. 
1.2 Insulin-resistant state as target for preventing T2D
T2D is driven by both insulin resistance (IR) and β-cell dysfunction. 
It is widely accepted that IR exists many years before overt diabetes, while 
hyperglycemia often appears with gradually impaired β-cell function (Fig. 1). 
This typical sequence of pathophysiological processes happens during the natural 
history in most patients with T2D. However, T2D is a heterogeneous disease, hence 
the stage of normal glucose tolerance but with IR is the potential target period for 
prevention, before IGT develops in such individuals.
But what can we do for individuals with normal glucose tolerance but an 
insulin-resistant state? To provide better prevention, we must first better understand 
the etiology of insulin resistance. 
1.3 Dyslipidemia as a possible causal factor of insulin resistance
The concept of insulin resistance was first postulated in the 1930s9. Two types 
of diabetic patients were differentiated by their blood sugar response to insulin 
therapy, and the description of the insulin-insensitive type represents the earliest 
research into insulin resistance. In the 1960s, hypertriglyceridemia was found to 
be related to IR10,11, but no compelling evidence for a causal relationship could be 
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discovered. In 1982, Steiner and Vranic postulated the “hypertriglyceridemia-IR-
hyperinsulinemia vicious cycle”12, which emphasized that hypertriglyceridemia 
could cause IR, while IR and compensatory hyperinsulinemia would aggravate 
hypertriglyceridemia. They pointed out that it should be possible to prevent T2D 
by intervening to control hypertriglyceridemia. This was a pioneering hypothesis 
at that time, although it only concentrated on hypertriglyceridemia due to the then 
limited studies on blood lipid profiles. 
However, at the Banting lecture (American Diabetes Association, New 
Orleans) in 1988, Reaven coined the term “syndrome X” (later changed to the 
more popular “metabolic syndrome”) to describe the cluster of metabolic disorders 
including dyslipidemia, hypertension, hyperglycemia, and central obesity, with 
IR postulated as the common cause13. Since then, a lot of evidence has supported 
the dominant hypothesis that IR can induce dyslipidemia14. Compensatory 
hyperinsulinemia due to IR can induce increased flux of free fatty acids, raise 
  Figure 1. A schematic view of the natural history in most patients with T2D. DPP: Diabetes 
Prevention Program of United States. DPS: Diabetes Prevention Study of Finland. Da Qing: Diabetes 
Prevention study of Da Qing, China. All three studies were designed to investigate how to prevent 
T2D in the IGT population. 
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production of triglycerides in the liver, and decrease high-density lipoprotein 
cholesterol (HDL-C). Thus, in contrast, by 1990’s dyslipidemia was believed to be 
a bystander rather than a causal factor.
Several years passed and knowledge of dyslipidemia increased dramatically. 
Recently, new evidence, including results from genome-wide association studies 
(GWAS), has revealed support for the old “vicious cycle” hypothesis15,16. However, 
we suggest replacing “hypertriglyceridemia” with “dyslipidemia” as it is not yet 
known which types of dyslipidemia could lead to insulin resistance. We propose 
a revision of the old hypothesis to: “dyslipidemia is a causal factor of insulin 
resistance”.
Here we should make it clear that we focus on “dyslipidemia” instead 
of “lipotoxicity”; the latter term, which was coined by Unger nearly 20 years 
ago17,18 means ectopic lipid deposition in the cells of non-adipose tissues such 
as liver, muscle, and heart19. In recent years, lipotoxicity has been accepted as 
one of the main mechanisms behind IR. Although lipotoxicity is associated with 
hypertriglyceridemia to some extent, they are not one and the same  disorder (Box 
1). We focus on “dyslipidemia” because we may be able to prevent T2D in the early 
insulin resistant stage by alleviating dyslipidemia (Fig. 1).
Could all types of dyslipidemia be possible causal factors of IR? On the 
one hand, it seems that only triglyceride and HDL-C are potential candidates 
rather than LDL-C. This is based on the Framingham Heart Study showing that 
hypertriglyceridemia and low HDL-C were more prevalent in T2D patients than in 
the normal population, while high LDL-C did not differ significantly in these two 
Box 1. Differences between dyslipidemia and lipotoxicity
Dyslipidemia Lipotoxicity 
Definition Abnormal serum lipoprotein concentrations Ectopic lipid accumulation
Location Circulation In the cell
Quantitative evaluation Blood test MRI 
Clinical marker Yes No 
Causing IR Possible Yes
Clinical use Easy Difficult 
Novel Mechanisms for Prevention and Treatment of Type 2 Diabetes48
groups20. This suggested that hypertriglyceridemia and low HDL-C, but not high 
LDL-C, might be causal factors of T2D. Various types of studies, including some 
GWAS-related research as shown below, support this inference.
On the other hand, both LDL-C and HDL-C can regulate β-cell function 
and survival in some in vitro and in vivo studies. LDL-C can decrease glucose-
stimulated insulin secretion of β-cells and inhibit proliferation, while infusion of 
HDL was shown to increase the β-cell insulin secretion and prevent apoptosis15,21. 
Since β-cell dysfunction and IR are tightly connected, it is possible that 
dyslipidemia might be a causal factor of both β-cell dysfunction and IR. However, 
because IR usually appears before β-cell dysfunction, it is considered the better 
target for preventing T2D. Hence, we focus here on the causal relationship between 
dyslipidemia and IR.
There is strong support for IR stimulating lipogenesis and cholesterol 
synthesis. Hence, excess amounts of free fatty acids are generated in adipose tissue 
and transferred to the liver, which results in the overproduction of very low-density 
lipoprotein (VLDL), increased plasma triglycerides and a reduction of HDL-C 
levels through the action of CETP (Cholesterol Ester Transfer Protein)14,22.
However, as this review suggests, dyslipidemia and IR may have a reciprocal, 
positive feedback relationship, i.e.,they may reinforce each other (Fig. 2). 
Hypertriglyceridemia and low HDL-C induce IR, while the consequence of IR 
aggravates dyslipidemia. This “vicious cycle” accelerates the development of IR in 
the early stages of the development of T2D. 
The mechanism through which hypertriglyceridemia and low HDL-C may 
Fig. 2. Possible relationship between dyslipidemia and insulin resistance.
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lead to IR still needs to be resolved. Lipotoxicity, inflammation and endoplasmic 
reticulum (ER) stress are three widely-accepted mechanisms known to induce 
IR23-25. Some human studies have suggested that high serum triglycerides seem 
to provoke a considerable amount of fatty acids to cells in ectopic lipid storage26. 
Lipotoxicity could thus be the main causal mechanism following dyslipidemia. 
However, it is also possible that dyslipidemia is a direct cause of inflammation, ER 
stress, or other mechanisms leading to IR in the absence of lipotoxicity. 
In this review, we focus on the evidence from human studies that supports 
the hypothesis that hypertriglyceridemia and low HDL-C may be causal factors of 
insulin resistance.
2. Epidemiological studies 
If hypertriglyceridemia and low HDL-C are causal factors in the development 
of IR, one would expect the two types of dyslipidemia to be able to predict 
future insulin sensitivity. Indeed, the Uppsala Longitudinal Study of Adult Men 
(ULSAM) has provided evidence that low HDL-C is a long-term predictor of 
insulin sensitivity27. The authors investigated 770 men who had participated in 
a health survey 20 years earlier and determined their insulin sensitivity through 
hyperinsulinemic euglycemic clamps. After adjusting for BMI as a confounder, 
low HDL-C levels proved an independent predictor of IR 20 years later, while 
triglycerides were not. There have been other longitudinal studies showing that 
hypertriglyceridemia, low HDL-C levels and/or the serum triglyceride/HDL-C 
index can predict future risk of developing T2D28-30. In the Framingham offspring 
study31, 1,004 offspring with baseline pre-diabetes were followed up for seven 
years and 118 new-onset T2D cases were recorded. Low HDL-C was proved to be 
one of the key non-glycemic traits that predicted later T2D in pre-diabetes (IGT 
or impaired fasting glucose, IFG) individuals. Although it is unfortunate that the 
latter study did not measure insulin sensitivity as an outcome, we can speculate that 
the deteriorating IR could be a primary cause of the ensuing decline of beta cell 
function. Combining the results from these epidemiological studies strongly implies 
that hypertriglyceridemia and/or low HDL-C play a role in the onset of IR, and can 
be used as one of the long-term predictors of insulin sensitivity.
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3. Genetic studies
3.1 Candidate gene studies
Two representative genes encoding proteins in lipoprotein pathways are also 
known to be involved in IR, thereby supporting a causal link between dyslipidemia 
and IR. These genes include the Lipoprotein lipase (LPL) gene and Apolipoprotein 
C3 (ApoC3).
In a case report of a familial lipoprotein lipase (LPL) deficiency, two affected 
sisters carried loss-of-function mutations in the LPL gene and they both suffered 
from insulin-resistant diabetes and severe hypertriglyceridemia. After their 
dyslipidemia was successfully treated by bilio-pancreatic diversion, the patients 
recovered from diabetes and oral glucose-tolerant tests showed completely normal 
results32. In addition, the glucose infusion rate of hyperinsulinemic-euglycemic 
clamp studies increased dramatically after surgery, indicating elevated insulin 
sensitivity. 
In another study, 85 heterozygous carriers of either a missense mutation 
(Gly188Glu) or a splice site mutation (C-->A in position -3 at the acceptor splice 
site of intron 6) in the LPL gene, were compared with 108 unaffected participants 
from the same families. The results showed that HOMA-IR (homeostatic model 
assessment-insulin resistance) index values were significantly higher in carriers 
than in non-carriers33. Furthermore, based on 12 single nucleotide polymorphisms 
in the 3’ end region of the LPL gene, which may change serum triglyceride 
levels by regulating LPL activity, the risk haplotypes for insulin resistance were 
discovered and replicated34. In hyperinsulinemic-euglycemic clamp studies in 
291 individuals from a large, family-based population, the same risk haplotypes 
were found to be related to the glucose infusion rate35. These studies thus provide 
evidence that loss of LPL gene function affects insulin metabolism. This is likely 
mediated through its effect on plasma triglyceride levels as well as lipid flux into 
the tissues. 
Another important gene encoding a protein in the pathway controlling VLDL-
TG levels is ApoC3, which is related to IR. In a study of 95 Asian Indian men, 
the T-455C and C-482T polymorphisms of the ApoC3 gene were found to be 
strongly associated with hypertriglyceridemia36. Moreover, it was found that the 
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prevalence of non-alcoholic fatty liver disease (NAFLD) was 38% among variant-
allele carriers, but absent among wild-type homozygotes (P<0.001). NAFLD is 
now known to be a hallmark of IR. The authors concluded that the polymorphisms 
C-482T and T-455C in ApoC3 are associated with NAFLD and IR. Because ApoC3 
is known as a protein inhibiting lipolysis of VLDL, the main effect of ApoC3 
mutations is a rise in VLDL-TG, and thus the present study greatly supports our 
proposed role for VLDL-TG in the etiology of IR. 
In conclusion, genetic data on LPL and ApoC3 show convincingly that 
while the primary cause of the mutations result in dyslipidemia, the secondary 
consequences lead to IR. In the absence of a direct role for LPL or Apoc3 in insulin 
resistance, these data do support a causal role of dyslipidemia in the etiology of IR. 
At the moment, there are no similar examples linking HDL metabolism to insulin 
signaling. 
3.2 Genome-wide association studies
Knowledge on the genetics of complex diseases has developed rapidly in 
recent years, especially since the completion of the Human Genome Project. 
The development of highly dense genotyping arrays has led to great success 
in identifying genetic variants using GWAS. So far, about 100 loci related to 
dyslipidemia37,38 have been reported and at least 9 loci for IR have been proposed39. 
Interestingly, several susceptibility loci have been found to be shared by both traits. 
For instance, both rs972283 for IR and rs4731702 for HDL-C are located near the 
KLF14 gene in 7q32.3 and are closely linked. In addition, rs11642841, which is 
located in the region of the well-known FTO gene for obesity and T2D, is closely 
linked with rs1421085 for the HDL-C trait. These might suggest common pathways 
for mechanisms involved in IR and hypertriglyceridemia/low HDL-C, which would 
be consistent with our hypothesis.
3.3 Mendelian randomization studies
Genetic association studies will not resolve what mechanism links SNP 
information to dyslipidemia and IR. For this purpose, the Mendelian randomization 
(MR) approach has been developed. MR is suitable to investigate the causal 
relationship between clinical observations (biomarker or intermediate/endo-
phenotypes) and disease outcomes using genetic information. The basic principle 
of MR is that if a biomarker (i.e., dyslipidemia in our hypothesis) is a causal factor 
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for the disease outcome (i.e., insulin resistance in our hypothesis), the genetic 
variation underlying this biomarker should also be associated with the disease. The 
association should be consistent with established epidemiological relationships, i.e., 
SNP alleles that increase total cholesterol (TC), LDL-C or triglycerides (TG) or that 
decrease HDL-C should be associated with an increased risk of IR. As genotypes 
are assigned randomly at birth when transmitted from parents to offspring during 
meiosis, MR is believed to act as a “natural randomized clinical trial”. As such, MR 
studies can help to test whether the association between a risk marker and outcome 
is causal or whether the marker is raised as part of the disease process (reverse 
causation)40. Following this approach, ten common genetic variants robustly 
associated with circulating triglyceride levels were studied in 5,637 T2D patients 
and 6,860 control subjects41. There was no evidence that carriers of greater numbers 
of triglyceride-raising alleles had an increased risk of T2D and higher levels of 
fasting-insulin or fasting-glucose. The data thus implied that hypertriglyceridemia 
was not a causal factor of IR41. In contrast, another more recent MR study drew the 
opposite conclusion that genetic predisposition to low HDL-C or high triglycerides 
was related to elevated T2D risk42. However, both studies had some limitations. 
The first study covered a limited number of genetic variants (10 loci accounting 
for only 3-5% of the variation in circulating triglycerides), while the second study 
covered 25 loci, jointly explaining nearly 10% of the genetic variation, but insulin 
resistance was not tested. A carefully designed MR study is needed to clarify the 
causal relationship between dyslipidemia and IR: including all established genetic 
loci of dyslipidemia, accurate phenotyping of IR cases, and a large sample size. 
4. Intervention studies 
Over the last few decades many lipid-modulating drugs have been introduced 
into clinical medicine. Classified according to their main target, these lower LDL-C 
or lower triglycerides, while recently, HDL-C raising drugs have been developed. 
In line with our revised hypothesis, we would expect the latter two to alleviate the 
development of insulin resistance, while the first would not. Unfortunately, since 
most clinical trials have studied the effectiveness and safety of the drugs in relation 
to cardiovascular outcomes, data on patients’ insulin sensitivity are limited to a few 
well-documented trials, which we will discuss below.
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4.1 LDL-C lowering treatments
So far, statins have been proven to effectively lower coronary artery disease 
(CAD) risk by reducing serum LDL-C. Their effects on serum triglycerides or 
HDL-C are moderate. However, over the last ten years, statin use has been reported 
to lead to an increase in the incidence of T2D. In 2010, a large meta-analysis 
included 13 statin trials with 91,140 participants43 and concluded that statin therapy 
was indeed associated with a slightly increased risk of developing T2D. Another 
meta-analysis included 16 trials with 1,146 participants and focused on insulin 
sensitivity, comparing the effects of different statins44. They found that pravastatin 
significantly improved insulin sensitivity, whereas simvastatin made it significantly 
worse. These results were consistent with earlier data from the West of Scotland 
Coronary Prevention Study (WOSCOPS)45, where the authors concluded that 
the assignment to pravastatin therapy resulted in a 30% reduction of developing 
diabetes. Without any data on insulin sensitivity, these authors speculated that 
pravastatin therapy might, at least partly, reduce the development of diabetes by 
lowering plasma triglyceride levels by as much as 12%. 
Pitavastatin is a potent novel statin with LDL-C lowering effects comparable 
to those of atorvastatin, but with some HDL-C raising effects (5.9-8.2% in general 
cohort and up to 22.4% in patients with low circulating HDL-C)46. In the LIVES 
study (n = 308), pitavastatin was found to significantly decrease HbA1c in diabetic 
patients47. The authors speculated that pitavastatin might raise HDL-C and thereby 
improve insulin sensitivity.
Ezetimibe, an intestinal cholesterol absorption inhibitor, can decrease LDL-C 
by approximately 20%, triglycerides by up to 8%, and raises HDL-C by 1-4%. A 
small clinical study with 75 participants showed that ezetimibe monotherapy for 12 
weeks effectively decreased HOMA-IR, along with improvement of serum LDL-C, 
triglyceride, and HDL-C levels48. Another small study with 45 patients investigated 
the long-term effect of ezetimibe in patients of NAFLD and found HOMA-IR 
and other abnormalities of NAFLD also improved significantly49. However, larger 
clinical studies are needed to validate these effects and more in-depth studies 
should investigate whether insulin sensitivity is improved through controlling 
dyslipidemia by LDL-C lowering therapies. 
Thus, some LDL-C lowering drugs act favorably by reducing HbA1c levels 
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or delaying the onset of diabetes. However, this beneficial effect appears to be 
inconsistent among all LDL-C lowering drugs. Moreover, statins have effects on 
inflammation, which could also lead to improved insulin sensitivity45. Other effects 
may be detrimental, including influence on β-cell function. These differences 
in response to the different drugs are of great interest to further understand the 
mechanisms of IR. 
4.2 Triglyceride lowering treatments
Fibric acid derivatives (fibrates), which are peroxisome proliferator-activated 
receptor (PPAR) alpha agonists, reduce serum triglyceride by 25-50% and raise 
HDL-C by 10-20%, while reducing LDL-C by 5-20%. Bezafibrate was found to be 
beneficial for delaying the development of pre-diabetes into diabetes in 199050. In 
subgroups of the Bezafibrate Infarction Prevention (BIP) trial with impaired fasting 
glucose (n=303), incidence of diabetes was seen to be lower in the bezafibrate 
treatment group than in controls51. In another subgroup of the BIP trial, a group 
of patients suffering from coronary artery disease treated by bezafibrate (n=1262) 
had significantly lower HOMA-IR values than the control group (n=1242) after 
two years of follow-up52. Thus, treatment with bezafibrate delayed onset of IR over 
two years. In addition, it has been shown in a group of 351 patients that treatment 
with bezafibrate can improve both IR (HOMA-IR) and β-cell function53. However, 
other studies on fibrates (including gemfibrozil, fenofibrate and bezafibrate) 
reached paradoxical conclusions54,55. Some research suggested that the mechanism 
via which PPAR alpha agonists improve IR was very complex and further basic 
studies are needed. It is therefore still too early to say whether triglyceride lowering 
treatment could delay insulin resistance in spite of some supporting evidence.
4.3 HDL modulating treatment 
Treatments modulating HDL metabolism are currently under development and 
only data of small scale studies are available. In a recent, double-blind, crossover 
study, reconstituted high density lipoprotein (rHDL) infusion in 13 patients was 
shown to lower plasma glucose levels significantly, while plasma insulin levels 
increased after 2.5 hours’ infusion56. Meanwhile, the HOMA-IR measurements 
in the rHDL and control groups showed no difference. The reduction of plasma 
glucose could not be explained only by enhanced β-cell function, because the 
reduction appeared before the elevation of plasma insulin levels. In skeletal muscle 
CHAPTER 3 Dyslipidemia as a Causal Factor in the Development of IR 55
cells it was demonstrated that the AMPK pathway was activated by rHDL56, 
which indirectly improved insulin sensitivity of the muscles. Interestingly, CETP 
inhibitors showed significant beneficial effects on IR in ILLUMINATE trial 
(n=6661), and were probably related to elevated serum HDL-C levels57.
In summary, intervention studies have shown that insulin sensitivity is 
improved by therapies to lower triglycerides and to modulate HDL, but robust 
insight into the exact mechanisms is still lacking.
5. Using systems genetics to understand disease etiology
One of the great promises at the current time is that systems genetics 
approaches will lead to much needed insight into the etiology of IR. In particular, 
because GWAS studies still leave a large proportion of the heritability unexplained 
and there is hot debate on the sources of this “missing heritability”. These 
limitations severely hamper the generation of robust mechanistic insights based on 
causality. Moreover, the current set of GWAS-based genetic loci has only limited 
power to deliver functional insight. It should be realized that most of the associated 
SNPs are not in coding regions and they are more likely to be involved in regulatory 
processes. With the greatly extended regulatory knowledge gained from ENCODE 
(the Encyclopedia of DNA Elements, http://genome.ucsc.edu/ENCODE/), the lead 
associated SNPs are, in most cases, in linkage disequilibrium with unknown causal 
variants58. These limitations reduce the power of an MR study and eventually limit 
our understanding of the disease etiology. Systems genetics approaches seek to 
understand complex disease traits by integrating systems biology approaches with 
those of genetics. Thus, in the post-GWAS era, these approaches are becoming a 
Box 2. Looking to the future: what research should be done to test our hypothesis?
1. We need longitudinal studies on large groups of dyslipidemia patients, especially on patients 
with monogenetic dyslipidemia, and intervention studies on dyslipidemia with insulin 
sensitivity as the main outcome.
2. We need carefully designed MR studies to clarify the causal relationship between dyslipidemia 
and IR, preferably including research in diverse ethnic groups. 
3. Further elucidation of the underlying etiology of IR will require a comprehensive approach 
involving genetic variation, intervention of environmental factors, systematic profiling of 
“omics” data, advanced statistical models, and functional studies in model organisms.
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powerful way of inferring causal roles from genotype to phenotypes. To understand 
the causal relationship between dyslipidemia and IR, we have to develop novel 
approaches, such as identifying the causal variants and genes of dyslipidemia 
from ENCODE and other bioinformatic data, treating those genetic variants as 
multifactorial perturbations in biological systems, and examining their effect on all 
aspects and traits related to IR. Subsequently, we should perform functional studies 
in model organisms and longitudinal studies in biological systems to confirm the 
findings. 
6. Conclusion
Unraveling whether dyslipidemia is a possible cause of insulin resistance 
is important, as it has many ramifications regarding the early diagnosis and 
prevention of T2D. LDL-C has been excluded as a relevant factor, since there is 
no evidence to support a causal relationship with IR. Hypertriglyceridemia and 
low HDL-C have been shown to be independent, long-term predictors of insulin 
sensitivity in longitudinal studies, while some genetic studies on genes related 
to hyperglyceridemia and/or low HDL-C have revealed that these genes are also 
linked to insulin sensitivity. Furthermore, controlling hypertriglyceridemia and low 
HDL-C has delayed onset of IR in some intervention studies. Additional genetic, 
MR and systems biology studies are now feasible and needed to confirm the causal 
role of hyperlipidemia in IR and its underlying mechanisms. Such studies will 
lead to urgently needed insight into ways to prevent insulin resistance and the 
subsequent development of type 2 diabetes.
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Abstract: 
Objective:To summarize our experience in the application of continuous subcutaneous insulin 
infusion (CSII) only as a method of rapid desensitization therapy for diabetic patients with insulin 
allergy and subsequent switching to the regimen of multiple dose injection for a long-time insulin 
therapy. 
Methods: The clinical data of 8 diabetic patients with insulin allergy in PUMC Hospital from 
April 2008 to December 2011 were retrospectively analyzed. 
Results: All 8 patients were diagnosed by case history, skin test, determination of serum 
specific anti-insulin IgE and reaction to withdrawal of insulin. Five patients accepted traditional 
injection method of desensitization, while 4 patients accepted CSII with the protocol designed by 
ourselves (1 patient accepted CSII after failure by the formal method). 4 of the 5 patients accepting 
the traditional method and all 4 patients accepting CSII succeeded. All patients accepted the regimen 
of multiple dosage injection as long-term insulin therapy. In a survey of 28 nurses, both experienced 
nurses and practical nurses preferred to use CSII as the method of desensitization. 
Conclusion: It is feasible and effective for diabetic patients with insulin allergy to merely use 
CSII as a method of rapid desensitization and subsequently switching to regimen of multiple dose 
injection for a long-term insulin therapy.
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Introduction
Patients with poor control of type 2 diabetes mellitus on maximum oral 
hypoglycemic therapy invariably need insulin therapy. In the adverse reactions of 
insulin therapy, insulin allergy is still a problem difficult to treat once it happens, 
although its incidence has dramatically decreased to less than 1% of diabetic 
patients receiving insulin therapy since the introduction of recombinant human 
insulin1. However, it results in potentially life-threatening immediate or delayed, 
local and general manifestations2. Though some cases suffered from protamine3, 
Zinc4 or meta-cresol5 of insulin preparations, usually it is persistent IgE-mediated 
insulin allergy (type 1 allergy)6, unresponsive to switching to different insulin type 
or the use of antihistamines, necessitates desensitization1,6. Different treatments of 
unequal efficiency have been proposed, a number of case reports and recent reviews 
have demonstrated that diabetic patients suffering from insulin allergy can be tolerated 
with continuous subcutaneous insulin infusion (CSII) since 19877-10. However, nearly 
all of those cases successfully treated by CSII accepted this type of therapy as the 
style of long time insulin therapy. Unfortunately, according to insurance policy 
in China, this expensive treatment is not covered for type 2 diabetic patients 
whatever they suffered from insulin allergy. Hence we had to attempt to use CSII 
as a method of desensitization instead of a long-term regimen of insulin therapy so 
that patients suffering from insulin allergy could spend as little money as possible. 
We retrospectively analyzed 8 cases of patients with diabetes all presented with 
local skin reactions after subcutaneous injection of different types of insulin 
preparations. The aim of this study is to investigate the possibility of adopting CSII 
as a method of rapid desensitization and then switching to the regimen of multiple 
dose injection (MDI) for a long-time insulin therapy.
Materials and Methods
We retrospectively analyzed medical records of 8 diabetic patients presented 
with local skin reactions after subcutaneous injection of different kinds of insulin 
preparations from clinical wards of endocrinology of the Peking Union Medical 
College Hospital from April 1st 2008 to December 31st 2011. They were treated with 
rapid insulin desensitization (4 patients with CSII, 5 patients with traditional rapid 
insulin desensitization, and among them 1 case experienced both methods). Data 
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of these patients were shown in table 1. The protocol of therapy had been approved 
by the appropriate ethical committees related to the Peking Union Medical College 
Hospital, and we did the insulin desensitization therapy after getting these patients’ 
written informed contents.
Before we started the insulin desensitization therapy, the patients should be 
evaluated whether insulin was the only therapeutic method to control their blood 
glucose. 
CSII desensitization protocol: 
We designed a protocol of CSII application in desensitization therapy 
according to the principle that immune tolerance might be induced by gradually 
increasing dosage from extremely small amount, and succeeded in the first pilot 
case11. The protocol was listed as follows in detail. The short action insulin 
preparation was diluted 10 times (from U100 to U10 by saline). The Minimed 
insulin pumps were used in all these patients (the first two patients with Minimed 
508C, the other three patients with Minimed 712 pump). The basal rate of diluted 
insulin began with 0.01 IU per hour of insulin, and then increased the basal 
infusion rate with the speed of 0.01 IU per hour on the first day of desensitization. 
At the end of the first day, the basal rate would increase to 0.24 IU per hour. If the 
patient was free of any symptoms of allergy, we would start the basal rate from 0.25 
IU per hour on the second day (using the U100 insulin without saline dilution), 
increased the rate by 0.05 IU per hour, till 1.4 IU per hour at the end of the second 
day. On the third day of desensitization, we kept the basal rate as 1.0 IU per hour 
or decreased to 0.5 IU per hour at night to avoid hypoglycemia in older patient, 
added on the bolus insulin infusion 4-6 IU before each meal with the insulin pump. 
After that, we gave the bolus insulin by subcutaneous injection using syringe with 
the basal insulin infusion by CSII at the same time on the fourth day. Finally we 
stopped using CSII, gave the patient with insulin therapy by multiple subcutaneous 
injection alternatively.
Results
Diagnosis of insulin allergy: 
The standard diagnosis protocol of insulin allergy was exclusion of poor 
injection technique and reaction to alcohol wipes first. Then insulin allergy was 
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diagnosed according to the following four respects. First, case history was checked 
to assure the symptoms and signs consistent with insulin allergy. Second, the 
description whether the patient’s reaction alleviated after insulin was retrieved was 
carefully reviewed and the clinical manifestations of all 8 cases disappeared after 
insulin therapy stopped. Third, serum specific anti-insulin Ig E to porcine, bovine, 
human insulin and specific anti-protamine Ig E in these patients were assessed. 
Last, Intra-dermal skin tests were performed with several insulin preparations to 
assist diagnosis of insulin allergy. All of the 8 cases were consistent with those four 
criteria for diagnosis of insulin allergy and needed insulin therapy inevitably (Table 
1). For case 4 and case 7, whose serum specific anti-human-insulin IgE could not 
be detected, we found they stopped usage of insulin for more than 3 months when 
they were determined; and serum specific anti-human-insulin IgE of Case 4 attained 
grade 2 when he was treated by insulin. Porcine regular, human regular and short-
acting human insulin analogs (including aspart and lispro) and NPH were used in 
the intra-dermal skin tests, the volume of all these kinds of insulin preparations 
was 0.1ml containing 1 unit insulin each, and we used saline as negative control 
(the volume was also 0.1ml). We did not include protamine, Zn, metacresol et al 
because these substances for diagnosis or therapy are not available in China. After 
the intra-dermal skin tests were performed, the situations of erythema and wheal 
were recorded immediately and carefully. 
Selecting one insulin/insulin analogue preparation for desensitization
Intra-dermal skin tests were performed with all types of insulin preparations 
listed above and the volume of each skin-test solution was 0.1ml containing 1 
unit of insulin, and saline was used as negative control. Based on the local skin 
reactions including the occurrence and disappearance time and the area size of 
erythema, wheal, induration or pseudopodia, one of the insulin preparations with 
the weakest reaction was selected as the one for desensitization (usually the regular 
insulin or short-acting insulin analogue).
Processes of desensitization 
According to the rules of desensitization, the process of insulin desensitization 
was performed under closely monitoring with preparations for emergency 
interventions in an inpatient setting11. There were 4 cases accepted CSII as the 
method of desensitization therapy while 5 cases accepted traditional desensitization 
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therapy (multiple dose injection) depending on the willingness of the patients, 
and one case accepted the former treatment after failing to tolerate insulin by the 
latter one. We used the pilot CSII desensitization protocol designed by ourselves 
for all the 4 cases who accepted CSII for desensitization (The protocol was listed 
in detail above in the Method section). Using this protocol, in the period of 3 days 
therapy all these 4 patients received CSII desensitization remained free of any 
symptoms of insulin allergy. We gave the bolus insulin by subcutaneous injection 
using syringe with the basal insulin infusion by CSII at the same time on the 
fourth day. After that, they were all successfully switched to insulin therapy by 
multiple subcutaneous injections with syringe. For other 5 patients, traditional 
desensitization protocol was applied according to the classical method1. 
Effects of two types of insulin desensitization therapy
All 4 cases who accepted CSII for desensitization were tolerated with 
the regimen of multiple dose insulin injection while 4 of 5 cases succeeded by 
traditional desensitization procedure. The unsuccessful one was case 1, and she 
finally agreed to use CSII protocol after the failure of traditional treatment of 
desensitization. After 3 days she was free of allergic symptoms and the regimen 
of insulin therapy was successfully switched from CSII to multiple subcutaneous 
injections by syringe on the fourth day. After the first following-up for 3-5 months, 
all these 4 patients using CSII for desensitization were free of any insulin allergic 
reactions by multiple subcutaneous injection therapy. 
The survey of the nurses’ opinion of CSII in the insulin desensitization 
therapy: 
The nurses with the experiences of operating insulin pump and those without 
were asked to fulfill the questionnaire of the convenience and the effectiveness 
of this method. If they didn’t use insulin pump before, they would answer 
the question, “If you have learned how to operate insulin pump, which kind 
of desensitization therapy do you prefer?” For the results, 15 nurses with the 
experience of operating insulin pump were all prefer the desensitization therapy by 
CSII to multiple injections by syringe. Other 13 practical nurses who finished the 
questionnaire would like to learn how to operate insulin pump, and then use this 
method in the desensitization therapy. The reason they preferred CSII therapy in the 
insulin allergic patients included that: it can mitigate the workload of them, avoid 
Novel Mechanisms for Prevention and Treatment of Type 2 Diabetes68
the stimulation of syringe needle, and decrease the error rate. 
Discussion
In the current study, we investigated the possibility of using CSII as a method 
of rapid desensitization instead of a long-term regimen of insulin therapy for 
diabetic patients allergic to insulin. The fact that all 4 cases accepting this protocol 
got the satisfactory effect suggests that CSII as a method of desensitization may be 
a good choice for those patients.
To use CSII only as a method of rapid desensitization instead of a long-term 
regimen of insulin therapy might be a good choice in the developing countries. 
Although CSII was introduced to treat insulin allergy as early as 19877, most cases 
accepted CSII regimen for whole life9. Only in 2012, a patient with insulin allergy 
had been treated by CSII successfully switched to multiple dosage injection one 
year later, was reported12. However, in many developing countries, CSII is still an 
expensive kind of insulin therapy so that most of the patients cannot pay for its 
expenses. According to our procedure, it is unnecessary for those patients to use 
CSII for whole life; it only costs the expenditure for renting an insulin pump for 
about 3 days. Furthermore, it is also unnecessary for patients to study how to use 
insulin pump; it could be managed by experienced nurses in the wards. Hence it 
is more practical to use CSII as only a method of desensitization in developing 
countries.
CSII is proposed to be an ideal method for treating insulin allergy in many 
literatures9,10, but more convincing data are needed to support this opinion. We 
tried to compare the effect between CSII and traditional regimen of desensitization, 
but the limited number of those rare cases restricted further analysis by statistics. 
From our data, it seemed that CSII was at least as effective as traditional regimen 
of desensitization. It was possible that CSII was superior to traditional regimen 
theoretically since CSII can make the dosage of insulin increasing more gradually 
and stably. In many case reports, CSII is always used after traditional regimen does 
not work. In the current study, there was also one patient who failed by traditional 
regimen but succeeded by CSII. Furthermore, we can conclude from the simple 
survey of nurses that CSII as a method of desensitization was widely accepted by 
nurses.
CHAPTER 4 CSII in insulin desensitization 69
In the current study, we designed a detailed protocol of CSII desensitization 
according to the principle of desensitization since most previous literatures did not 
provide a standard protocol or simply used CSII as common. The practice of this 
protocol in 4 cases certified its feasibility.
 There were some shortcomings in our series of cases analysis. First, it was a 
retrospectively observational study, but it would be controversial in medical ethics 
if we decided the regimen randomly instead of based on each patient’s will. Second, 
we could not detect protamine, Zn cation, meso-cresol et al because the relative kits 
are not available in China. Third, because the sample size was not large enough, 
we cannot compare the effect of two types of desensitization regimen statistically, 
although it was the largest clinical study about CSII application in insulin allergy 
till now. Large sample, well-designed, multi-centered clinical studies are needed to 
investigate whether CSII will be the first choice of desensitization. 
In conclusion, it is possible and effective for diabetic patients to merely 
use CSII as a method of rapid desensitization and then switch to the regimen of 
multiple dose injection for a long-time insulin therapy. This procedure is favored 
by nurses in the clinical ward because of lower workload and error rates. Further 
studies are needed to evaluate the advantage of CSII in insulin desensitization.
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Abstract: 
Both anti-insulin antibody induced hypoglycemia and anti-insulin antibody induced 
hyperglycemia are rare diseases. We provided either a case of them and both were more difficult 
than typical case. The first case is a patient whose clinical investigation was typical as anti-insulin 
antibody induced-hypoglycemia but serum anti-insulin antibody was negative; he was diagnosed by 
column chromatography successfully. The second case is a patient whose daily insulin dosage was 
about 800IU but serum insulin level was 0mmol/L, finally diagnosed by recovery test. Either case was 
treated effectively by immunosuppressive therapy. The process of diagnosis suggested that application 
of laboratory methods would be useful in some rare diseases. A novel classification of insulin-related 
antibody induced dysglycemia is suggested according to pathogenesis.
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Introduction
Autoimmune hypoglycemia is a rare disease. In 1960 Harwood1 reported on a 
34-year-old woman with type 1 diabetes who demonstrated insulin resistance (140 
to 180 U insulin/d) but also intermittent episodes of severe hypoglycemia. The 
patient's serum contained anti-insulin antibody with high insulin binding capacity 
and a slow rate of dissociation of insulin-antibody complexes. It was postulated 
that insulin was "stored" at high levels in the serum bound to anti-insulin antibody, 
and that the slow rate of dissociation of insulin from the complex composed with 
insulin and anti-insulin antibody resulted in intermittent hypoglycemia. In 1970 
Hirata2 nominated Insulin autoimmune syndrome (IAS, or Hirata’s disease) to 
describe the condition of hypoglycemia, elevated insulin levels, and high levels of 
anti-insulin antibody in individuals never exposed to exogenous insulin therapy. 
These patients usually had a history of taking drugs with sulphydryl compounds. 
Most of the cases were Japanese, and there were over 40 cases3 in China. In 
fact, autoimmune hypoglycemia has also been reported4 in the patients receiving 
recombinant human insulin therapy. It is the insulin-antibody complex, which 
releases the free insulin intermittently, directly causes hypoglycemia despite 
that the antigen is endogenous or extrinsic insulin. Therefore, it is important for 
diagnosis of autoimmune hypoglycemia that the anti-insulin antibody is positive. 
Here we report a case that the clinical investigation was similar as autoimmune 
hypoglycemia but anti-insulin antibody was negative; and we succeeded to confirm 
the existence of macromolecular protein complex containing insulin in serum by 
column chromatography.
Meanwhile, the complex composed with insulin and anti-insulin antibody 
can induce not only hypoglycemia but also severe hyperglycemia, although it is 
extremely rare. We also reported a case whose daily insulin dosage attained 800IU 
but serum insulin level was 0mmol/L, finally diagnosed as anti-insulin antibody 
induced hyperglycemia.
Case 1
A 77-year-old Chinese male patient was admitted to our hospital because of 
intermittent hypoglycemic attacks for 5 months. The patient had type 2 diabetes 
mellitus for three years and was on treatment with acarbose until he turned to 
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insulin therapy because of the partial resection of rectum one year earlier. His 
fasting blood glucose level (FBG) was 5-7mmol/l and postprandial blood glucose 
level was 8-11mmol/l by NPH 8IU subcutaneous injection before every breakfast. 
6 months earlier the patient felt fatigue, palpitated and perspired with the serum 
glucose 2.2mmol/l, and the symptoms were relieved after eating some candy. After 
that the hypoglycemic attacks happened 4-6 times every month, most of which 
occurred before dawn, and the lowest serum blood glucose level attained 1.8mmol/
l. There were still intermittent hypoglycemic episodes after the insulin therapy 
changed to treatment of nateglinide or arcabose. The patient had taken catopril 
for 2 years and clindamycin once, which were drugs containing sulfhydryl group. 
Laboratory test showed HbA1c 6.3%, and anti-insulin antibody negative. When the 
hypoglycemia attack was confirmed, we found serum insulin and C-peptide levels 
were very high (see Table 1, 2). Imaging findings including Multi-slice spiral CT 
perfusion scan did not reveal any tumor in pancreas. 
Considering the possibility of the false negative of anti-insulin antibody 
determination, we drew the venous blood of the patient and isolated the serum, 
and separated the serum by column chromatograph and collect the No.11- 100 
dilutions. Then insulin and adiponectin levels of each dilution were determined by 
Fasting 0.5hr 1hr 2hr 3hr
Blood Glucosel level (mmol/L) 4.42 6.27 11.98 18.31 15.58
Insulin (uIU/ml) 95.90 102.00 107.00 177.00 237.00
C-peptide (ng/ml) 5.26 5.17 6.85 >7 >7











1 1.2 3.4 127.84 67.7 33.1
2 2.3 4.0 71.71 43.5 79.3
3 2.3 5.6 167.71 22.4 40.7
Table 2. Serum insulin, C-peptide and proinsulin levels at the hypoglycemia episode 
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ELISA. The insulin level of No. 17 dilution rose obviously, and the peak value, 
which attained 65 times than baseline, occurred in the No.22. The peak value of 
the adiponectin occurred in the No. 16 and No. 27 dilutions (Figure 1). Hence 
the existence of insulin-bound protein was proved and the complex composed 
of insulin and anti-insulin antibody was most possible. Therefore, anti-insulin 
antibody induced hypoglycemia was suspected.
After that, the patient accepted prednisone 30mg QD and symptom of 
hypoglycemia relieved about a week later. We decreased prednisone gradually and 
stopped it 4 months later. The patient did not have hypoglycemia during 6 months 
follow-up visit.
Discussion of diagnosis
Autoimmune hypoglycemia is a rare disease. Before autoimmune 
hypoglycemia is diagnosed, we need to exclude insulinoma and malignant tumor 
Figure 1. Insulin and adiponectin levels of the serum dilution after column chromatography
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which also can cause hypoglycemia. In this case, the serum insulin level of the 
patient was very high when he had hypoglycemia, which indicates insulinoma, but 
there are not positive findings in pancreatic perfusion CT, ultrasonic endoscope and 
99mTc-octreotide scintigraphy. The sensitivity of perfusion CT to detect insulinoma 
is nearly 100% these days5,6. Considering the high sensitivity of pancreas perfusion 
CT and the patient is maransis, the insulinoma was nearly excluded. Malignant 
tumors which lead to hypoglycemia could not explain serum high insulin level. 
Hence autoimmune hypoglycemia seemed to be the possible diagnosis.    
Most cases of autoimmune hypoglycemia are caused by anti-insulin antibody, 
but we should also be aware of insulin receptor antibody, which can cause 
hypoglycemia too. Usually insulin receptor antibody is an antagonist to insulin 
receptor and results in severe insulin resistance; but in very rare situations, it can 
act as agonist and results in hypoglycemia. The hypoglycemia of the patient is not 
caused by insulin receptor antibody because he had high serum C peptide. The 
clinical feature of the hypoglycemia caused by anti-insulin antibody is paroxysmal 
hypoglycemia, which is caused by unpredictable dissociation of antigen and 
antibody compound. For this reason, the detection of anti-insulin antibody is very 
important for making a diagnosis. While we should notice there are many factors 
affecting the accuracy of anti-insulin antibody determination.    
In present, the purpose to detect anti-insulin antibody is for diagnosing type 
1 diabetes mellitus instead of autoimmune hypoglycemia. In most hospitals that 
can run anti-insulin antibody test, ELISA and CLIA have replaced RIA becoming 
the first choice to determine anti-insulin antibody. In these two methods, insulin 
special fragment is taken as coating antigen and is coated at tubal wall, the second 
antibody is anti-IgG-Fc fragment antibody attaching enzyme active group or 
fluorescence active group; when there is anti-insulin antibody in serum, it will 
bind with insulin special fragment coated at tubal wall, and then bind with tagged 
second antibody. After incubation, anti-insulin antibody will anchor at tubal wall 
and be detected. In type 1 diabetes mellitus, insulin is absolutely deficient, if there 
is anti-insulin antibody, its amount will be relatively large and test result will be 
more reliable. But in patient with autoimmune hypoglycemia, the serum insulin 
level is normal and most anti-insulin antibody bind with insulin, which cause 
coating antigen (insulin fragment) at tubal wall competes with serum antibody-
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insulin compound and inhibits antibody anchoring at tubal wall. Most anti-insulin 
antibody is discarded in supernatant and the test result is negative. Consequently 
in autoimmune hypoglycemia caused by anti-insulin antibody, the false negative 
result using ELISA and CLIA to test anti-insulin antibody is possible.   
In this case, we attempt to prove there is large amount of antibody-insulin 
compound in patient serum, which cause his hypoglycemia. We separate serum 
proteins according their molecular weight by column chromatography, then test 
insulin level in each tube and determine the peak value. At the same time, we also 
test adiponectin level and its peak value. We can see two adiponectin peak values 
in figure 1, which is in common with the fact that there are two types of molecular 
weight adiponectin. The insulin peak appears between the two adiponectin peak, 
which means molecular weight of the under testing substance is between these 
two kind adiponectin, in another saying, is larger than 150KD, far larger than 
molecular weight of insulin which is 5.7KD. We deduce this substance is a protein 
compounded with insulin. The most possible protein is anti-insulin antibody for 
molecular weight of IgG is 150KD. It seems to be more likely that there is another 
peak of free insulin, but the result of chromatography indicates that all of the 
insulin molecules in the serum sample are bound to anti-insulin antibodies at room 
temperature. Hence we can make a diagnosis of this patient hypoglycemia, which 
is autoimmune hypoglycemia caused by anti-insulin antibody.
Case 2
A 71-year-old male patient diagnosed as Type 2 diabetes mellitus for 18 
years and accepted Insulin therapy for about 3 years, was admitted to PUMCH for 
recurrent ketosis for last 3 months and DKA twice on Sept.6th, 2010, while the total 
amount of insulin dosage he used per day was 650-800 IU. Meanwhile, the blood 
glucose concentration could not be controlled yet.
He was diagnosed as type 2 diabetes mellitus in 1992 and began to receive 
the oral antidiabetic drugs such as metformin and glibenclamide. Then he accepted 
insulin therapy (Gansulin Mix 30®) due to poor glycemic control in 2007. After 
that, his fasting serum glucose levels maintained 7-8mmol/l when the total insulin 
amount used per day was 40IU. However, the patient felt more and more fatigue, 
accompanied with polyuria, thirsty and polydipsia since spring of 2010, and the 
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fasting glucose level was as high as 20mmol/l. Although the daily dosage increased 
to more than 100 IU gradually, the blood glucose control of the patient was not 
improved at all. On the contrary, he had suffered from recurrent ketosis, and had 
been diagnosed as diabetic ketoacidosis twice since the end of May, 2010. In the 
process of treatment of DKA, he was transfused intravenously with insulin and his 
daily dosage increased to 500-800 IU to prevent the recurrence of DKA but the 
blood glucose level remained between 12 to 20mmol/L. His weight dropped 27 kg 
in half a year. And he had a dumb feeling in both feet for about half a year. Finally 
he was admitted to PUMC Hospital.
On examination, the patient appeared extremely slim, intravenously infused 
with recombinant human regular insulin by an intravenous pump. His weight 
was 53kg and his height was 165cm. His blood pressure was 110/68mmHg, 
and the pulse was 84 beats per minute, and the body temperature was normal. 
Electrocardiography, echocardiography and abdominal ultrasound were normal. 
Laboratory data revealed severe hyperglycemia (25mmol/L) and obviously high 
urinary glucose concentration. HbA1c was 10.7% although the patient suffered 
from slightly anemia (Hb 112g/L, reference range 120-160g/L). Chest X-ray 
showed patchy shadows in the right pulmonary lobe and Chest CT revealed 
multiple patchy shadows in the right middle lobe. PET-CT showed parts of the 
shadows with high uptake of 18F-FDG.
When the blood glucose attained 25mmol/L and the patient was intravenously 
infused with recombinant regular human insulin continuously, we drew his blood 
sample from the lateral forearm and determined the serum insulin and C-peptide 
level. The result of serum insulin level was 0mIU/L while the serum C-peptide was 
2.1mmol/L, which was completely inconsistent.
Hence recovery test was done to test what had happened. After adding insulin 
solutions by insulin standard substance, saline and bovine serum albumin, which 
final theoretical concentrations would have been 18.1mmol/L and 33.3mmol/
L, respectively, the practical concentrations were determined to calculate either 
recovery rate. However, both results were 0mmol/L, which meant the recovery 
rate was 0%. The serum anti-insulin antibody concentration was determined 
immediately but the exact value could not be acquired because it was more than the 
upper limit of the reference 0-10mIU/L. 
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Diagnosis of anti-insulin antibody induced hyperglycemia was determined and 
the plasma exchange therapy started. But the clinical effect was not satisfactory 
after using this treatment 3 times (every other day). Hence the immune-suppressive 
therapy was adopted and he took prednisone 30mg per day and mycophenonate 
5mg three times a day. After initiation of immune-suppressive therapy, the total 
dosage of insulin was dropped gradually and infusing insulin intravenously was 
substituted by multiple subcutaneous injections, and the patient was discharged.
4 months later, the patient was followed up in outpatient clinic. The total 
dosage was decreased to 35IU/d and HbA1c was 7.3%. His dosage of prednisone 
was reduced to 30mg and mycophenonate was 5mg twice a day. Repeated Chest CT 
revealed that there was no change in multiple patchy shadows in the right middle 
lobe.
Discussion of diagnosis
Although we could diagnose the patient as severe insulin resistance 
syndrome only according to his daily insulin dosage, anti-insulin antibody induced 
hyperglycemia was the most appropriate diagnosis since it revealed the mechanism 
of the disease and provided the possible treatment. 
The first key point of diagnosis was to determine serum insulin level when the 
patient was intravenously transfused with insulin. According to the regular dogma 
of endocrinologist, measuring insulin was not permitted when the patient accepted 
insulin therapy. But the fact that such large dosage of infused insulin could not 
lower blood glucose level was so wired that we believed serum insulin level would 
give us some useful information. However, the result that serum insulin level was 
0mmol/L was extremely surprising, which meant two possibilities – enzyme which 
could hydrolyze insulin or high molecular protein which could bind insulin and 
mask the isotopes of insulin in the patient’s blood. Then we did the recovery test.
The recovery test was the second point of diagnosis and it excluded the 
possibility of enzyme hypothesis. After the freshly concentrated prepared insulin 
solution was added to the patient’s serum in vitro, the insulin level measured was 
still 0mmol/L. Since activity of enzyme will drop rapidly in the room temperature, 
the hypothesis of enzyme could be excluded. Meanwhile, the hypothesis of high 
molecular protein could explain this situation: there should be so large amount of 
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such protein in the patient’s blood that all of the added insulin could be bound. And 
result of measurement of anti-insulin antibody proved this hypothesis and revealed 
that anti-insulin antibody was the high molecular protein we were looking for. 
Although chest-CT and PET-CT suggested possibilities of malignant tumor, 
no clear evidence can provide any clues explaining the relation between malignant 
tumor and anti-insulin antibody. We did not have any evidence of lymphoma, while 
senior respiratory physician was inclined to the diagnosis of bronchiectasis based 
on the results of chest-CT. Since PET-CT was performed when the patient had 
experienced a long period of severe hyperglycemia, the nonspecific shadows with 
high uptake of 18F-FDG were considered to be result of hyperglycemia without 
diagnosis value. Follow-up of this patient confirmed our diagnosis.
Finally, we made it clear that anti-insulin antibody band both the infused 
recombinant human insulin and endogenous insulin so that no insulin in the 
patient’s blood could have any effect, which caused hyperglycemia and its acute 
complications directly.
Discussion of treatment
Plasma exchange was selected as the first choice because it was believed to 
clear the serum antibody directly and to improve the clinical symptoms rapidly7. 
However, it didn’t acquire the ideal effect after the patient accepted it for a 
week. Hence we adopted the immuno-suppressive therapy with prednisone and 
mycophenolate, which was commonly used in autoimmune diseases and was 
effectively used in some similar cases7,8. As a result, the blood glucose was well 
controlled and the daily insulin dosage decreased dramatically. And follow-up of 
this patient demonstrated the effectiveness of immune-suppressive therapy.
Discussion of classification of insulin-related antibody 
induced dysglycemia
These two cases are both induced by anti-insulin antibody, although the 
clinical investigations are completely opposite. However, based on the same 
mechanism, the treatments of the two cases are similar. It is reasonable that they 
should be classified to two subtypes of one disease. Unfortunately, these two cases 
have to be classified to completely different categories according to their clinical 
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symptoms: autoimmune hypoglycemia and severe insulin resistance syndrome. 
Although the current classification is useful for clinical physicians, we still believe 
that a new classification according to mechanism of disease is also useful to guide 
treatments and will be more useful in the future (Table 2, Fig. 2). First, we classify 
insulin-related antibody induced dysglycemia as three categories according to 
different etiology of immune response. Mechanism of the first category is that 
insulin antibody induces autoimmune attack to beta cells, which finally develops to 
type 1 diabetes9. The second category is induced by insulin-receptor antibody. This 
type of antibody always binds on insulin receptor of the surface of target cells. If 
the antibody belongs to antagonist, it will induce hyperglycemia (often called type 
B insulin resistance); if the antibody is a kind of agonist, it will induce persistent 
hypoglycemia, similar as mechanisms of Graves’ disease. The third category is 
induced by circulating antigen-antibody complex, while insulin is the special 
antigen. Extremely high binding capacity between antibody and insulin will make 
all the insulin molecules unable to bind with insulin receptor, which will cause 
severe hyperglycemia such as case 2 in this article. If the binding capacity is not 
very high while the amount of antibody is large, paroxysmal hypoglycemic attacks 
will happen when large amounts of insulin molecules are dissolved from antigen-
antibody complex. And we also can speculate antigen epitope from the reaction of 
therapy of insulin analogues, while the current IAS patients can be classified to one 
subgroup with specific antigen epitope(s). One case was successfully treated by 
insulin analogue Lispro10, which is possibly due to avoiding antigen epitope. Hence 
it will be important in the future to differentiate those subgroups according to 
antigen epitopes; when most common antigen epitopes of insulin can be identified 
in clinical assay and various types of insulin analogues can be selected, we can 
use special insulin analogues in order to avoid specific epitopes in most of those 
patients. 
In this article, we provide two rare cases induced by anti-insulin antibody. 
Anti-insulin antibody induced hypoglycemia is relatively common, but the case 
with false negative determination of anti-insulin antibody is rare and difficult. 
Anti-insulin antibody induced hyperglycemia was extremely rare, and the case 
with serum insulin level being 0mmol/L has not been reported in literature. The 
common characteristics of these two cases is not only caused by the same antibody, 
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Insulin-related antibody induced dysglycemia
Category Type 1 diabetes Insu l in- receptor 
antibody induced 
dysglycemia
I n s u l i n  a n t i b o d y  i n d u c e d 
dysglycemia
Mechanism I n s u l i n  a n t i b o d y 
induced autoimmune 
attack to beta cell
Antibody acts as a 
legend of insulin 
receptor
Circulating complex composed 
by insulin and insulin antibody 
influences the concentrations of free 
insulin.




Cross antigen for 
mercap to  Group 
(Hirata disease)
Antigen epitope Ident i f ied in 
the future
N e a r  m e r c a p t o 
group of insulin
Table 2. Classification of insulin-related antibody induced dysglycemia
  F ig .  2 .  Three  d i ffe ren t 
mechanisms of insulin-related-
antibody-mediated dysglycemia. (2-
1) Insulin antibody induces β-cell 
damage through complimentary 
system, ADCC, etc. This situation 
often causes type 1 diabetes, 
following with hyperglycemia. (2-
2) Insulin-receptor antibody induces 
dysglycemia through binding with 
insulin receptor. When it acts as 
agonist, the patient will suffer from 
hypoglycemia (2-2a); when it acts as 
an antagonist, severe hyperglycemia 
happens (2-2b). (2-3) Complex 
of insulin antibody and insulin in 
circulation causes dysglycemia. If 
the binding capacity is extremely 
high, patient will suffer from 
persistent hyperglycemia (2-3a); if 
binding capacity is not very high 
but the concentrations of antibody 
are high, hypoglycemic attacks will 
happen frequently (2-3b).
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but also diagnosed through the laboratory experiments based on basic medicine. 
The first case is diagnosed through column chromatography, while the second is by 
recovery test. Based on mechanism revealed by these two cases, we suggest a new 
classification of insulin-related antibody induced dysglycemia.
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Abstract: 
OBJECTIVE: Dyslipidemia is strongly associated with raised glucose levels and its clinical 
endpoint of type 2 diabetes (T2D). However, the causal nature of this relationship and the effect of 
lipid genes on T2D remain unclear. The identification of lipid SNPs in genome-wide association 
studies has enabled the use of polygenic risk scores to assess the nature of the relationship between 
lipids and glucose-related traits. 
RESEARCH DESIGN AND METHODS: We used 95 common genetic variants that were 
robustly associated with triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol 
(LDL-C) or high-density lipoprotein cholesterol (HDL-C). We calculated polygenic scores for blood 
lipids in 13,105 subjects of the LifeLines cohort and in a replication sample of 3649 subjects from 
the PREVEND cohort. Then we computed Spearman correlations of each genetic score with fasting 
plasma glucose, HbA1c levels and HOMA-IR. We further performed meta-analysis to combine 
the effects of individual lipid SNPs on glucose-related traits in LifeLines and PREVEND using a 
weighted Z-score approach. 
RESULTS: We found no associations between lipid risk scores and glucose-related traits 
except for a weak negative correlation between the TG risk score and HbA1c (r=-0.025, p=0.01). 
However, after adjusting for circulating lipid levels, higher TG, LDL and TC risk scores and a lower 
HDL risk score are correlated with lower levels of glucose-related traits. Specifically, the TG risk 
score was positively correlated with TG levels (r=0.19, p=4.2×10-91 in LifeLines; r=0.21, p=4.5×10-25 
in PREVEND) but negatively correlated with fasting glucose (r=-0.058, p=9.6×10-10 in LifeLines; 
r=-0.044, p=0.03 in PREVEND), HbA1c (r=-0.048, p=4.2×10-7 in LifeLines) and HOMA-IR (r= 
-0.07, p=6.2×10-4 in PREVEND). In LifeLines, we also observed similar negative correlations 
between glucose-related traits and the LDL risk score (r=-0.029, p=2.6×10-3 for fasting glucose; r= 
-0.035, p=2.2×10-4 for HbA1c) or TC (r=-0.022, p=0.019 for fasting glucose; r=-0.038, p=5.7×10-5 
for HbA1c). The HDL risk score was positively correlated with both HDL and fasting glucose levels 
(r=0.036, p=1.8×10-4 in LifeLines; r=0.063, p=1.9×10-3 in PREVEND), HbA1c (r=0.028, p=0.003 in 
LifeLines) and HOMA-IR (r=0.113, p=3.2×10-8 in PREVEND). Furthermore, we identified 15 loci 
at p<0.01 level with pleiotropic effects on lipids and glucose-related traits, and 8 of them (APOB, 
GCKR, TIMD4, MLXIPL, CYP7A1, CETP, APOE-C1-C2 and PLTP) have shown significant 
associations with these two traits opposite to the expected phenotypic directions. 
CONCLUSIONS: Our polygenic risk models for lipids show weak but highly significant 
protective effects on fasting plasma glucose, HbA1c and HOMA-IR levels. These paradoxical 
protective effects are caused by pleiotropy as they are independent of the lipid levels. 
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Introduction
Dyslipidemia, which includes increased circulating concentrations of total 
triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol 
(LDL-C) and/or decreased circulating high-density lipoprotein cholesterol (HDL-C) 
levels, is known to be strongly associated with insulin resistance (IR) and type 
2 diabetes (T2D). This is especially true for hypertriglyceridemia and decreased 
HDL-C levels as these are important components of the metabolic syndrome. 
Current wisdom dictates that the relation between dyslipidemia and IR and/
or T2D is explained by a causal effect of IR and/or T2D on dyslipidemia. IR may 
cause compensatory hyperinsulinemia and high plasma free fatty acids (FFA), 
which may induce hypersecretion of very-low-density lipoprotein cholesterol 
(VLDL-C) subsequently leading to dyslipidemia1-3. However, in the current study 
we will explore two often neglected alternative explanations.  
The first possibility is that instead of IR and/or T2D causing dyslipidemia the 
reverse may be true, i.e., dyslipidemia may cause IR, leading to higher levels of 
glucose and related traits and eventually T2D. This explanation is consistent with 
evidence from some epidemiological studies. Circulating HDL-C level has been 
shown to be a predictor of future IR or T2D4,5, while some lipid-lowering therapy 
can reduce the incidence of T2D6,7. With the identification of over 90 lipid loci in 
genome-wide association studies (GWASs)8 a method has emerged that enables 
testing the direction of causal relationships. The effects of lipid genes are combined 
in genetic risk scores (GRSs), which can be used as proxies for blood lipid levels 
to test their causal effect on glucose-related traits through a polygenic model. This 
is also known as the Mendelian Randomization approach9. A similar study was first 
performed by De Silva et al10, who detected no significant effects of TG genes on 
fasting glucose level, IR and risk of T2D concluding that TG is not a causal factor 
for these traits. Another study by Qi et al11 adopted a similar design, but found 
positive effects for TG and HDL-C GRSs indicating these lipids may be causally 
related to glucose-related traits and outcomes. As the only two previous studies 
testing this hypothesis reached opposite conclusions, larger studies using GRSs 
containing more lipid SNPs are warranted. 
A third possibility explaining the relation of dyslipidemia with IR and/or T2D 
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is pleiotropic effects of genes independently influencing both lipids and glucose-
related traits. It seems increasingly clear that closely associated phenotypes often 
share genes and pathways, especially for common complex diseases12,13. Results 
from the GWAS catalog show that 16.9% of genes and 4.9% of SNPs show 
pleiotropic effects14. Also for dyslipidemia and T2D (or other glucose-related traits) 
one would expect many genes to have pleiotropic effects on these traits. However, 
only 5 lipid genes (GCKR, FADS1, IRS1, KLF14 and HFE) also showed genome-
wide significant effects on T2D or glucose-related traits in spite of GWASs having 
discovered over 95 loci for dyslipidemia8 and about 50 loci for T2D15 in recent 
years. This is inconsistent with the expectation of abundant pleiotropy of complex 
diseases and traits. It is still possible that pleiotropic genetic effects of lipid genes 
on glucose-related traits may be too small to identify in GWASs, which also can be 
tested by the polygenic model.
We performed the current polygenic risk model analysis to further investigate 
the relationship between lipid genes and glucose-related traits using the LifeLines 
and PREVEND studies with data available on both genotype and phenotype in 
more than 15,000 subjects. The aims (Fig. 1) are: 1). To test whether GRSs of lipid 
genes are correlated to glucose-related traits (Path A); 2). To test whether lipid 
genes have pleiotropic effects on glucose-related traits (Path B). Furthermore, 
we performed single SNP association to test the impact of lipid SNPs on glucose 
related traits, before or after adjusting for circulating lipid levels. 
  Fig. 1. The possible relation between lipid genes and glucose-related traits 
(according to principles of Mendelian randomization approch16). In this article we 
investigated the effects of lipid genes on glucose-related traits. The effect could 
be indirectly mediated through blood lipid levels (Path A); it also could be direct, 
independent from blood lipid levels (Path B).
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RESEARCH DESIGN AND METHODS
Study cohort
The study was approved by the Ethics Committee of the University Medical 
Centre Groningen.
The LifeLines cohort. In this study we used 13,105 genotyped unrelated 
subjects derived from the LifeLines cohort study, a large cohort study of 
representative Caucasian residents in three Northern provinces of the Netherlands 
which will include 165,000 participants17. All participants underwent a medical 
examination at baseline since the end of 2006 and will be followed for 30 years. 
This study used the clinical measures at the baseline. TC was measured with an 
enzymatic colorimetric method, HDL-cholesterol with a colorimetric method, and 
TG with a colorimetric UV method. Fasting plasma glucose (FPG) was measured 
with a hexokinase method. The HbA1c level was measured using a turbidimetric 
inhibition immunoassay but standardized against the reference method of the 
International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). 
The LDL cholesterol concentration was calculated using the Friedewald equation. 
More details were described in the previous paper18,19. Fasting insulin was not 
measured in the LifeLines cohort preventing calculation of HOMA-IR.
The PREVEND cohort. We used a subset of 3,649 genotyped unrelated 
subjects from the Prevention of REnal and Vascular ENd stage Disease (PREVEND) 
study, which is an ongoing prospective study since 1997 investigating the natural 
course of increased levels of urinary albumin excretion and its relation to renal 
and cardiovascular disease. The initial cohort consisted of 8,592 subjects. This 
study used the clinical measures at baseline. HDL cholesterol was measured with 
a homogeneous method (direct HDL, AEROSETTM System, Abbott Laboratories, 
Abbott Park, U.S.A.). Triglycerides were measured on a Mega multi-analyzer 
after enzymatic splitting with lipoprotein lipase (GPO PAP, Merck, Darmstadt, 
Germany). Total cholesterol and plasma glucose were assessed using Kodak 
Ektachem dry chemistry (Eastman Kodak, Rochester, New York, U.S.A.). Insulin 
was measured with an AxSym® auto-analyzer (Abbott Diagnostics, Amstelveen, 
The Netherlands). The details of the protocol for measuring HDL, TG, TC, FG and 
insulin levels have been described before20,21. The LDL cholesterol concentration 
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was calculated using the Friedewald equation. The homeostasis model assessment 
of insulin resistance (HOMA-IR) was calculated by (glucose×insulin)/22.5. The 
HbA1c level was not measured in PREVEND cohort.
The selection of subjects
This study we only included the clinic measures of fasting blood samples from 
non-diabetes individuals. Diabetes was defined by any one of the following criteria 
if applicable: 1) self-reported diabetes; 2) FPG ≥7.0 mmol/L; 3) HbA1c ≥6.5%; or 
4) taking anti-diabetic medicines. We also excluded the individuals taking lipid-
lowering medicines. The participants should be fasting for 8 hours before clinic 
measurements. We did not exclude the individuals with anemia, as we did not 
observe any significant impact of anemia on HbA1c level (T-test P value 0.44). 
Thus the final study population comprised 10,995 LifeLines subjects and 2,438 
PREVEND subjects. The clinical characteristics of the cohort are summarized in 
Table 1. 
Table 1: Clinical characteristics of Cohorts
LifeLines PREVEND
Number of Individuals 10,995 2,438
Covariates
       Sex (Male/Female) 4,441/6,554 1158/1280
       Age (mean + s.d.) 47.5 + 10.7 49.8 +12.5
       BMI (mean + s.d.) 26.1 + 4.1 26.1 + 4.2
Lipids (mean + s.d.)
       HDL-C (mmol/l) 1.46 + 0.39 1.33 + 0.40
       LDL-C (mmol/l) 3.34 + 0.88 4.06 + 1.09
       TC (mmol/l) 5.16 + 0.98 5.67 + 1.07
       Log10(TG) 0.03 + 0.22 0.08 + 0.23
Glucose-related traits (mean +s.d.)
       FPG* (mmol/l) 4.96 + 0.48 4.77 + 0.62
       HbA1c (%) 5.50 + 0.31 NA
       Log10(HOMA-IR†) NA 0.23 + 0.28
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Genotyping, imputation and quality control.
Both LifeLines and PREVEND cohorts were genotyped using Illumina 
HumanCytoSNP-12 BeadChip. The un-genotyped SNPs were imputed by program 
Beagle using HapMap 2 release 24 as the reference panel. We used the best guess 
imputed genotype for this study. The quality control was described before18. 
SNP selection
A list of lipid SNPs on 95 unique loci was reported from the largest meta-
analysis up to date8; different lipids can have different best SNPs in the same locus. 
The risk alleles and their effect size were extracted for each SNP and each lipid 
type. We further excluded three SNPs that genotypes were not imputed in LifeLines 
and PREVEND. They are rs13238203 at TYW1B locus; rs2412710 at CAPN3 
and rs1800961 at HNF4A. Thus we included 129 lipid-associated SNPs into this 
study, including 46 SNPs for HDL cholesterol (Sup Table 1), 37 SNPs for LDL 
cholesterol (Sup Table 2), 30 SNPs for TG (Sup Table 3) and 51 SNPs for TC (Sup 
Table 4). 
Risk score calculation
For each lipid and for each individual, the un-weighted risk score and weighted 
risk score were calculated respectively. The un-weighted risk score was calculated 
as the total number of the risk alleles per individual. For the weighted risk score, the 
risk alleles were weighted by their estimated effect size. We further re-scaled the 
risk scores between 0 and 1 by dividing the risk scores by the maximum risk. Thus 
the un-weighted risk model can be described as  ; where gij is the 
number of risk alleles for jth SNP in ith individual, coding as 0 for homozygous non-
risk alleles, 1 for heterozygous genotype or 2 for homozygous risk alleles; n is the 
total number of associated SNPs per lipid trait. The weighted risk score is described 
as  ; where  βj refers to the estimated effect size 
for the jth SNP. 
Association between the lipid risk score and phenotypes
The TG levels and HOMA-IR level were log10 transformed. The residual 
lipid levels and glucose-related traits were obtained using linear regression model 
adjusting for covariates: age, age2, and sex. The model is described as yi = agei + 
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age2i + sexi+ei ; where yi refers to an observed lipid level or glucose related trait 
(FG, HBA1C or HOMA-IR) for ith individual and ei is the remaining residual. The 
residuals were used as phenotypic trait and subject to the Spearman correlation 
analysis with the lipid risk scores. To tested the potential pleotropic effect of lipid 
genes on glucose-related traits, we further regressed out the effect of lipids on 
glucose-related traits using the model yi = agei + age
2
i + sexi+HDLi + LDLi + TGi + 
TCi + e'i ; where yi refers to glucose-related trait (FG, HbA1c or HOMA-IR) of ith 
individual and e' refers to the residuals for glucose traits that are independent from 
lipid levels. The residuals were used as lipid-independent glucose traits and subject 
to Spearman correlation with lipid risk scores.
Single SNP association
To test the association between glucose-related traits and individual lipid 
SNPs, we performed linear regression analysis between the SNP genotype and 
each phenotypic trait. We further performed meta-analysis to combine the effect of 
LifeLines and PREVEND using a weighted Z-score approach. The significance of 
individual SNP was controlled at P<0.01. 
Result
Observed association between lipid risk scores and lipid levels.
We observed the significant positive correlation between lipid risk scores 
and the lipid levels observed in our cohorts (Supplementary Table 5, Fig. 2). 
The weighted risk scores outperformed the un-weighted risk score, explaining 
substantial proportion of variation in lipid levels: 4.95% for HDL, 3.61% for LDL, 
3.61% for TG and 4.41% for TC in LifeLines; 3.69% for HDL, 1.90% LDL; 4.37% 
TG and 2.07% for TC in PREVEND cohort. It suggests the weighted risk score 
is a better genetic predictor for the lipid levels. Thus we used weighted risk score 
for the further analysis. The single SNP association per lipid and the meta-analysis 
across Lifelines and PREVEND cohorts was shown in Supplementary Table 2. 
Based on this meta-analysis at P value 0.01 level, we replicated the association for 
21 HDL SNPs, 17 LDL SNPs, 12 TG SNPs and 21 TC SNPs (Supplementary Table 
1-4).  
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No association between lipid risk scores and glucose-related traits except 
a weak negative correlation between triglyceride risk score and HbA1c.
We assessed three different glucose-related traits in two independent cohorts: 
fasting glucose from both LifeLines and PREVEND cohort, HbA1c from LifeLines 
and HOMA-IR from PREVEND. After adjusting for the covariates, age, age2 and 
sex, we observed significant correlation between glucose-related traits and the 
lipids levels. Consistently with epidemiological observations, individuals who have 
higher level of LDL, TG and TC levels or have lower HDL levels tend to have 
higher level of glucose-related traits (Table 2). The strongest correlations were 
mostly observed for TG. However, despite the strong correlation at phenotypic 
level, we did not observe the correlation between lipid risk score and glucose-
related traits, except a weak negative correlation between triglyceride risk score 
and HbA1c level in LifeLines (r = - 0.025, P = 0.01) (Sup Table 6). 
Figure 2: The relationship between lipids and lipid risk scores in Lifelines.
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Pleotropic association between lipid risk scores and glucose-related traits.
We further regress out the phenotypic correlation structure between lipids 
and glucose-related traits and obtained lipid-independent glucose traits. To our 
surprise, we observed, at genetic level, an opposite effect between dyslipidemia 
and glucose-related traits: higher TG, LDL and TC risk score or lower HDL risk 
score were correlated with lower glucose-related traits (Table 3). Specifically, 
triglyceride risk score were positively correlated with triglyceride level (p=4.2×10-91 
in LifeLines and p=4.5×10-25 in PREVEND) but negatively correlated with fasting 
glucose (p=9.6×10-10 in LifeLines, p=0.03 in PREVEND), HbA1c (p=4.2×10-7 
in LifeLines) and HOMA-IR (p=6.2×10-4 in PREVEND). In LifeLines, we also 
observed the similar negative correlation between glucose-related traits and the risk 
scores of LDL or TC. Contrary to other lipid types, HDL risk score were positively 
correlated with HDL level and also positively correlated with fasting glucose 
level (p=1.8×10-4 in LifeLines and p=1.9×10-3 in PREVEND), HbA1c (P=0.003 in 
LifeLines) and HOMA-IR (P=3.2×10-8 in PREVEND). Our analysis suggests that 
the negative genetic effect is overlooked due to the strong phenotypic correlations 
in the opposite direction.
Single SNP association
At P value 0.01 level, we detected the association at 18 lipid SNPs on 15 
unique loci with lipid-independent glucose-related traits: 11 SNPs for fasting 
Table 2: The phenotypic correlation between lipids and glucose-related traits
HDL (mmol/L) LDL (mmol/L) Log10(TG) TC (mmol/L)
LifeLines
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glucose level, 8 lipid SNPs for HbA1c and 9 SNPs for HOMA-IR (Figure 3 & 
Sup Table 7). Consistent with the findings of polygenic risk score, 8 of the 15 
SNPs (APOB, GCKR, TIMD4, MLXIPL, CYP7A1, CETP, APOE-C1-C2 and 
PLTP) showed effect directions opposite to the expected phenotypic direction of 
association between glucose-related traits and lipids. We also compared the allelic 
direction of lipid SNPs on glucose-related traits before and after adjusting for 
lipids. Their directions were consistent but the associations became stronger after 
adjusting for lipid levels (Sup Table 8). This shows that our results are unlikely 
to be explained by some artifact induced by correcting for phenotypic correlation 
structure. 
Discussion 
In the current study, we investigated the relationship between lipid genes and 
3 glucose-related traits by polygenic risk model analyses in the large LifeLines 
Table 3: The Spearman correlation between lipid risk score and lipid-independent glucose trait
LifeLines
FPG (mmol/l) HbA1c (%)
HDL risk scores r = 0.036
p = 1.8×10-4
r = 0.028 
p = 0.003
LDL risk scores r = -0.029 
p = 2.6×10-3
r = -0.035 
p = 2.2×10-4
TG risk scores r = -0.058 
p = 9.6×10-10
r = -0.048 
p = 4.2×10-7
TC risk scores r = -0.022 
p = 0.019




HDL risk scores r = 0.063
p = 1.9×10-3
r = 0.113 
p = 3.2×10-8
LDL risk scores r = 0.028 
p = 0.17
r = -0.003 
p = 0.88
TG risk scores r = -0.044 
p = 0.030
r = -0.07 
p = 6.2×10-4
TC risk scores r = 0.018 
p = 0.38
r = 0.001 
p = 0.96
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database with replication in PREVEND. First, we examined the relationship 
between genetic risk scores for each lipid trait and FPG, HbA1c or HOMA-IR 
(path A in Fig. 1), but found no significant associations except for a weak inverse 
correlation between the TG genetic score and HbA1c. These results do not support 
the hypothesis that dyslipidemia has a causal effect on glucose-related traits. These 
findings are in line with those from a previous study by De Silva et al.10, as in fact 
they also found an inverse relationship between the TG genetic score and risk of 
Figure 3: The allelic direction Comparison
  X-axis: Z-score of meta-analysis combining the effect of LifeLines and PREVEND. Black dots: significant 
at P<0.01 level both in our database and in the literatures. Gray dots: significant in the literatures. Open dot: not 
significant. Bold: genes with opposite effects on lipid and glucose-related traits. 
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T2D or FPG, which is difficult to explain. However, a similar study performed 
by Qi et al. obtained contradictory results showing that genetic scores of TG or 
HDL-C can predict risk of T2D11. These inconsistent findings based on studies 
with similar designs have so far failed to improve our insight into the relationship 
between lipids and glucose traits. Hence we tested an alternative explanation of 
the relation between lipids and glucose-related traits through pleiotropic effect of 
lipid genes (Path B in Fig. 1). Unexpectedly, we observed significant associations 
between genetic risk scores of each type of lipid genes and glucose-related traits 
after adjusting for circulating lipid levels with directions opposite to the expected 
phenotypic relationships. This means that alleles increasing TG, TC or LDL-C 
and alleles decreasing HDL-C have protective (i.e., lowering) effects on glucose-
related traits. Furthermore, we detected 18 individual SNPs at 15 loci significantly 
correlated to at least one lipid - glucose trait combination.
Of the 15 loci (APOB, GCKR, TIMD4, LPA, HLA-B, MLXIPL, NPC1L1, 
CYP7A1, FADS1-2-3, LRP1, LACTB, CETP, APOE-C1-C2, TOP1 and PLTP) 
with pleiotropic effects on lipids and glucose-related traits, only GCKR and FADS1 
had been reported in previous GWASs to have effects on both traits. We did not 
confirm the pleiotropic effects of INS1, KLF14 and HFE in our database. Although 
all are associated with plasma lipid levels, their functions in lipid metabolism 
vary and have not been completely elucidated. We classified these genes into four 
categories. First, some of those genes encode plasma proteins closely associated 
with lipoproteins, including APOB and APOE-C1-C2. Second, some genes encode 
key enzymes or other functional proteins in lipid metabolism, including MLXIPL, 
FADS1-2-3, NPC1L1, CYP7A1, CETP and PLTP. MLXIPL is also named 
ChREBP and encodes a glucose-responsive transcription factor that binds to the 
promoter of several lipogenic genes. The third category includes GCKR, which 
encodes glucokinase regulatory protein (GKRP), a protein inhibiting the activity 
of glycokinase, a key enzyme of glycolysis. Some evidence suggests that activity 
of glycokinase will influence the amount of the substrate of de novo lipogenesis 
affecting the blood lipid profile22. Other genes including TIMD4, HLA-B, LRP1, 
LACTB, LPA and TOP1, constitute the fourth category and are involved in a 
variety of physiological processes. TIMD4 and HLA-B are both associated with 
immune-related disorders, and LRP1 encodes an endocytic receptor involved in 
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many physiological processes, including lipid homeostasis. LACTB encodes a 
protein component of ribosome while TOP1 encodes a DNA topoisomerase for 
transcription. The pleiotropic effects of those genes may be due to more common 
physiological processes. 
The most surprising results of the current study are that higher genetic risk 
scores of TG, TC and LDL-C and lower genetic risk scores of HDL-C predict lower 
FPG, HbA1c and HOMA-IR. In the discovered 15 shared loci associated with 
both lipids and glucose-related traits, 8 loci (APOB, GCKR, TIMD4, MLXIPL, 
CYP7A1, CETP, APOE-C1-C2 and PLTP) show significant associations with these 
two traits opposite to the expected phenotypic directions. Although this situation 
is paradoxical, more and more genes are being found to have similar pleiotropic 
effects, such as PNPLA3 for TG and T2D in obese individuals23, GRB14 for WHR 
and FPG, SLC39A8 for BMI and HDL-C24. However, its significance remains 
unclear. GCKR was the first gene for which opposite effects on lipid and glucose-
related traits were reported25. When the glucose-lowering allele reduces the activity 
of GKRP, the activity of GCK will increase and de novo lipogenesis will speed up, 
which eventually causes increased synthesis of TG. Furthermore, TG in hepatocytes 
will induce lipotoxicity and hypertriglycemia, which may induce IR and down-
regulate the activity of GCK, thus acting as a “negative feedback system”. 
However, GCKR is more a glucose gene than a lipid gene. It remains to be seen 
how pleiotropic effects of the other genes can be explained. From an evolutionary 
perspective, all of the 8 genes are highly conserved, which suggest that opposite 
pleiotropic effects may be common in evolution26,27. 
In conclusion, we tested the effects of lipid genes on glucose-related traits by 
polygenic model analyses, and found that lipid genes have pleiotropic effects on 
fasting plasma glucose levels, HbA1c and HOMA-IR. The most notable finding 
is that these pleiotropic effects are opposite to the directions of the phenotypic 
associations, which means that individuals with more alleles increasing TG, TC and 
LDL-C and decreasing HDL-C would have lower plasma glucose levels, HbA1c 
and HOMA-IR. We also detected 15 gene loci having pleiotropic effects, and 8 
of them were revealed to produce opposite effects on blood lipids and glucose-
related traits. Further research investigating the underlying mechanisms of these 
pleiotropic effects is warranted. 
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Trait Weighted Risk Score Unweighted risk score
LifeLines
HDL risk (47 snps)  vs HDL r = 0.24 
p= 1.5×10-139
r = 0.17 
p= 3.2×10-70
LDL risk (37 SNPs) vs LDL r = 0.19 
p= 2.0×10-87
r = 0.15 
p = 3.1×10-59
TG risk (30 SNPs) vs TG r = 0.19 
p = 4.2×10-91
r = 0.16 
p = 1.2×10-60
TC risk (51 SNPs) vs TC r = 0.21 
p = 1.9×10-107
r = 0.18 
p = 6.8×10-82
PREVEND
HDL risk vs HDL r = 0.192 
p = 3.3×10-21
r = 0.142  
p = 2.60 ×10-12
LDL risk vs LDL r = 0.138 
p = 1.1×10-11
r = 0.111 
p = 5.54 ×10-08
TG risk vs TG r = 0.209 
p = 4.5×10-25
r = 0.166 
p = 3.33 ×10-16
TC risk vs TC r = 0.144 
p = 8.4×10-13
r = 0.107 
p = 1.33 ×10-07
LifeLines
FPG Level HbA1c Level
HDL risk score r = -0.002 
p = 0.81
r = 0.004 
p = 0.66
LDL risk score r = -0.012 
p = 0.19
r = -0.009 
p = 0.33
TG risk score r = -0.015 
p = 0.13
r = -0.025 
p = 0.01






HDL risk score r = 0.024 
p = 0.23
r = 0.037 
p = 0.069
LDL risk score r = 0.046 
p = 0.024
r = 0.018 
p = 0.39
TG risk score r = -0.008
p = 0.71
r = 0.035 
p = 0.087
TC risk score r = 0.034 
p = 0.095
r = 0.021 
p = 0.29
Supplementary Table 6:  The Spearman correlation between the weighted risk score and 
glucose-related traits adjust for covariants
Supplementary Table 5: Correlation between lipid risk scores and observed lipid levels in 
Lifelines and PREVEND
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SNP A1 A2 After adjusting lipids Before adjusting lipids
Z score P value Z score P value
FPG
rs1260326 C T 5.9 5.4×10-9 4.05 5.40×10-5
rs3764261 A C 3.69 2.2×10-4 1.2 0.097
rs1042034 T C -3.41 6.0×10-4 -1.87 0.034
rs7205804 A G 3.28 9.2×10-4 1.17 0.10
rs7811265 A G -2.96 2.5×10-3 -1.81 0.039
rs4810479 C T -2.95 2.5×10-3 -2.08 0.023
rs4420638 A G 2.92 2.8×10-3 1.53 0.062
rs17145738 C T -2.8 3.9×10-3 -1.65 0.051
rs1030431 G A 2.67 5.7×10-3 2.21 0.017
rs4297946 G C -2.57 7.4×10-3 -2.81 3.8×10-3
rs174550 C T -2.52 8.4×10-3 -1.88 0.034
HbA1c
rs1042034 T C -3.78 1.62×10-4 -2.98 2.9×10-3
rs17145738 C T -2.76 5.72×10-3 -2.39 0.017
rs3741414 C T 2.64 8.3×10-3 2.75 5.9×10-3
rs4420638 A G 3.01 2.6×10-3 1.25 0.21
rs4810479 C T -3.91 9.2×10-5 -3.41 6.6×10-4
rs6065906 C T -2.94 3.3×10-3 -2.42 0.016
rs7205804 A G 2.6 9.2×10-3 1.12 0.26
rs7811265 A G -2.89 3.8×10-3 -2.52 0.012
HOMA-IR
rs1553318 C G -3.21 1.3×10-3 -2.1 0.036
rs1564348 T C -2.7 7.0×10-3 -3.05 2.3×10-3
rs17145738 C T -2.61 9.0×10-3 -1.07 0.28
rs217386 A G -2.71 6.6×10-3 -3.03 2.4×10-3
rs2247056 C T 2.64 8.2×10-3 2.5 0.012
rs2652834 G A 3.12 1.8×10-3 1.92 0.054
rs3764261 A C 5.21 1.8×10-3 3.13 1.8×10-3
rs7205804 A G 4.16 3.2×10-3 1.96 0.05
rs7811265 A G -2.72 6.5×10-3 -1.2 0.23
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Numerous achievements in diabetes have been made for nearly a hundred 
years, including those that won seven Nobel Prizes. Similar to the work of most 
medical scientists, our research in this thesis will also contributes to the treatment 
and prevention of T2D. However, the road to conquer diabetes fully is still very 
long. Almost every clinical endocrinologist sometimes feels frustrated by diabetes, 
since we cannot prevent the progress of its chronic complications effectively with 
our current regimens, in particular the macrovascular complications including 
cardiovascular diseases. New targets for therapy or prevention still need to be 
identified to improve the prognosis for T2D.
Another awkward fact about T2D is based on its heterogeneity. Experienced 
endocrinologists are always frustrated by some well-controlled diabetic patients 
who progress rapidly to suffer from chronic complications; while a few patients 
whose plasma glucose levels are continuously high enjoy their lives freely without 
complications. Hence, this hetereogeneity only seems to be explained by genetics. 
However, we cannot differentiate between these two types of diabetic patients 
when they are diagnosed with T2D. What we can do is use a trial-and-error method, 
adjusting each regimen according to each patient’s response in order to make 
the patient’s regimen as near perfect as possible, which is called “personalized 
medicine”. Eventually, endocrinologists hope to have a method and especially some 
biomarkers to predict these situations, which new developments in genetics might 
provide some chance of finding, fortunately.
1. Personalized Medicine in Ancient Times
Personalized medicine, according to its literal meaning, is patient-centric 
medicine. Hence, personalized medicine dates back to ancient Greek times, when 
medicine was separated from witchcraft. “The physician must not only be prepared 
to do what is right himself, but also to make the patient, the attendants, and 
externals cooperate”, Hippocrates said1. Therefore, personalized medicine in fact 
appeared when medicine was introduced.
In ancient China, “treat the same disease with different regimens, while 
treating different diseases with the same regimen” was one of the most important 
principles of Chinese traditional medicine. The essence of this principle is that the 
correct treatment is based on careful observation of the patient and analysis, not 
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merely experience. For instance, a patient considered to be diagnosed with diabetes 
would often be classified as “Up Jiao”, “Middle Jiao” and “Down Jiao” after 
carefully taking a case history and making a physical examination. If a patient was 
diagnosed as “Down Jiao”, he was believed to suffer from diabetic nephropathy 
and his regimen would be different from that prescribed for patients of the other 
two categories.
At that time, the main problems of personalized medicine were lack of 
information for an accurate diagnosis and a lack of effective treatments. Some 
regimens of Chinese traditional medicine could alleviate the symptoms of diabetes 
but could not effectively lower blood glucose, so that those treatments could not 
delay the progress of diabetes.
Thus, we have had personalized medicine since ancient times, but few 
effective methods for diagnosis and few effective treatments.
2. Personalized medicine in modern medical practice
There has been much progress made in medicine in the past 100 years and the 
progress in basic science has provided us with not only the fields of physiology and 
pathophysiology, but also various types of methods of diagnosis and treatments. 
This progress has made personalized medicine more important and effective.
2.1 Accurate classifications of diseases are one big step of personalized 
medicine
Correct classifications of diseases are very important for personalized 
medicine. In Ancient time, diseases always were diagnosed only according to 
symptoms and clinical signs. Hence quite a few of patients would be misdiagnosed 
and personalized medicine could not be effective. In ancient China, thirsty and 
emaciation were characteristics of diabetes; but sometimes patients of untypical 
hyperthyroidism would be misdiagnosed as diabetes so that they could not be 
correctly treated by personalized medicine. However, measurement of blood 
glucose levels gave us an accurate method of differential diagnosis so that we can 
effectively treat diabetic patients. Classification of T1D and T2D by Himsworth in 
1936 was also very important for personalized medicine, so that oral anti-diabetic 
drugs could be used only for patients of T2D correctly. 
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2.2 Heterogeneity of complex diseases and importance of personalized 
medicine
Personalized medicine is especially important for complex diseases like T2D. 
T2D is a typically heterogeneous disease, which is actually a group of metabolic 
disorders with the same characteristics of raised blood glucose levels. We have 
to use the nomination of “T2D” because we do not know enough to make a more 
detailed and accurate classification. The current classification of diabetes for clinical 
endocrinologists includes T1D, T2D, gestational diabetes, and other specific types 
of diabetes. When the mechanism of one group of special diabetic patients was 
discovered, such as maturity-onset diabetes of the young (MODY), this subgroup 
was then excluded from T2D and reclassified as a specific subtype of diabetes. 
Although progress in genetics and other subjects have identified some specific 
subtypes of diabetes, the remaining group of T2D patients is still heterogeneous. 
For some patients, beta cell dysfunction is the main cause of T2D, while for other 
patients, IR may be the most important cause. Different situations need different 
treatments. As described in Chapter 1, there are several options for treating T2D; 
hence we always have to use the old method of “trial-and-error” (observation and 
adjustment) to attain the goal of personalized medicine.
3. Current Situations for Personalized Medicine
3.1 Flourishing of evidence-based medicine (EBM) and rise of 
personalized medicine
EBM has been the main stream in modern medical practice since the 1990s 
and had a positive influence on people’s health2. Almost every common disease has 
its own guidelines for diagnosis and treatment; these effectively steer professional 
medical behavior worldwide. However, sometimes the guidelines are mis-used and 
principles of personalized medicine are neglected. In Italy, a similar percentage 
of various regimens for T2D were adopted in patient populations of different 
ages and even with different renal function3. This will lead to poorer outcomes. 
Such situations also exist in other countries4. American Diabetes Association and 
European Association for the Study of Diabetes therefore gave their annual position 
statement a new name of “a patient-centered approach”5. Furthermore, we should 
be very careful to evaluate a new drug in clinical trials on specific patient cohorts. 
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For instance, an example from another disease is Trastuzumab, a monoclonal 
antibody that binds the HER2/neu receptor: it is effective for the patients of breast 
cancer with overexpression of HER2. However, such patients are generally less 
than 30% of all patients with breast cancer6. If we only use data from the clinical 
trials for general populations of breast cancer patients, this effect would never have 
been discovered. Therefore, personalized medicine is more and more important for 
clinical behavior and research.
3.2 Basic medicine offers possibility of detailed classifications and new 
treatments
As described in 2.2 of this chapter, for personalized medicine it is 
important to classify diseases into detailed categories, so that treatments will be 
appropriate. Progress in basic medicine continues to help us make better and better 
classifications according to the disease etiology. In Chapter 5, we summarized a 
group of patients with insulin-related IgG-induced dysglycemia and reclassified 
them according to types of antibody, antigen, and antigen epitopes. Although this 
classification cannot directly guide the treatment of these diseases today, in the near 
future, when we can determine each antigen epitope of these patients and when 
we have various types of insulin analogues, it should be effective. In Chapter 4, 
we described some patients with insulin allergy. Though we succeeded in using 
desensitization by CSII, the best treatment for these cases is to determine which 
specific epitope of insulin induces allergy for each patient, and use the personalized 
insulin analogue without that specific epitope.
Sometimes basic medicine is especially effective for the personalized 
treatment of some rare diseases. In Chapter 4, we described two rare cases. We used 
column chromatography to help identify the existence of insulin-binding proteins 
in the first case, and we applied the recovery test in the second case to implicate 
the existence of the insulin-antibody complex, although the serum insulin level was 
zero. Although both cases were effectively treated by immunosuppressive therapy, 
the personalized design for each case was the key to making an accurate diagnosis. 
3.3 Genetics and personalized medicine
Rapid progress in genetics has revealed the mechanisms of many diseases, 
especially monogenic diseases. For diabetes, at least 27 monogenic subtypes have 
been identified so far7. As mentioned before, this is a big step towards a more 
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personalized treatment.
The most successful example is neonatal diabetes mellitus (NDM). Although 
NDM was recognized more than 200 years ago, genetic etiologies for NDM have 
mainly been defined in over the past 20 years8. Several genes were identified for 
NDM, including IPF1, GCK, PTF1A, and GLIS3. In 2004, KCNJ11 was identified 
as one of causal genes of NDM in a case report9. Though scientists speculated that 
NDM was different from type 1 diabetes, the regimen of insulin therapy is generally 
accepted as the most appropriate treatment. However, the cases of mutations in 
KCNJ11 or ABCC8 can be successfully treated by sulfonylurea instead of insulin. 
KCNJ11 encodes one subunit of the ATP-sensitive potassium (KATP) channel, 
while ABCC8 encodes other subunit, which is also the receptor for sulfonylurea 
drugs. Hence it is possible to treat these two types of NDM with sulfonylurea 
drugs, and subsequent clinical reports confirmed the effect10. Every patient with 
NDM should be tested for these two types of mutations before proposing a therapy 
regimen. Cost-effectiveness studies also showed that genetic testing could lower 
the total cost of treatment11. Therefore, KCNJ11 and ABCC8 are now tested as 
new biomarkers for this specific subtype of NDM, which illustrates a successful 
example of personalized medicine.
MODY is another example of personalized medicine. Although MODY was 
seen as a specific subtype of T2D for a long time, because age of onset was in 
adolescence, the principle of treatment for MODY was not very different to that 
for ordinary T2D patients. However, when the causal genes for various subtypes 
of MODY were identified, personalized treatments were applied and their effects 
improved greatly. MODY2 is caused by mutations of glucokinase, a key enzyme 
of glycolysis – a slightly higher blood glucose levels will accelerate glycolysis. 
MODY1 and MODY3 are due to mutations of HNF4alpha and HNF1alpha, 
respectively: both mutations can increase sensitivity to sulfonylurea drugs. Hence, 
the treatment for MODY2 is not pharmacotherapy, except if the patient is pregnant, 
but simple lifestyle intervention. The first choice of treatments for MODY1 and 
MODY3 should be low-dosage sulfonylurea. MODY1, MODY2, and MODY3 
account for 87% of all MODY patients and this personalized therapy means that 
most MODY patients are given the most appropriate treatment12.
Apart from unraveling monogenic diabetes, genetic studies have also made 
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progress in other respects. The most influential progress was the completion of the 
Human Genome Project (HGP), which made personalized medicine a hot topic. 
4. Personalized medicine reinterpretated by NIH: waiting 
to be decoded
Personalized medicine has become increasingly popular in the past 15 years 
because of the Human Genome Project, which was completed in 2000. According 
to bibliometric studies, the amount of literature on “personalized medicine” 
increased rapidly just after the completion of HGP13. The US National Institutes of 
Health (NIH) defined personalized medicine as “an emerging practice of medicine 
that uses an individual’s genetic profile to guide decisions made in regard to the 
prevention, diagnosis, and treatment of disease”14.
Compared to past eras, the current problem of personalized medicine is 
not due to limited methods, but to too much information that we cannot (yet) 
understand. It is similar to having an encyclopedia written in ancient Egyptian 
hieroglyphics and waiting for it to be decoded. More and more studies are now 
focusing on how to understand and exploit all the genetic and genomic information 
available.
5 .  Persona l i zed  Medic ine  in  the  Near Future: 
Pharmacogenetics and Pharmacogenomics 
As an important branch of genetics, pharmacogenetics aims to study 
how genetic variation affects drug response, including pharmacokinetics, 
pharmacodynamics, and side-effects15. Before the HGP, pharmacogenetics 
had revealed a lot of information about personalized medicine, while 
pharmacogenomics was using genomic technology to extend pharmacogenetics 
since the completion of the HGP16. For diabetes, there have been quite a few 
pharmacogenetic and pharmacogenomic studies on oral anti-diabetic drugs17,18 and 
some examples of pharmacogenetic studies are given below.
5.1 Sulfonylureas
KCNJ11 and ABCC8 encode two subunits of the KATP channel of beta cells. 
Hence, it is easy to understand that polymorphisms of these two genes will alter 
the effects of sulfonylurea drugs10,19. However, CYP2C9 is a gene encoding a 
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rate-limiting enzyme that can eliminate sulfonylureas, which could affect their 
hypoglycemic effects by altering their blood concentration20,21. If, in an individual 
patient, one type of sulfonylurea is both slowly eliminated and sensitive to the KATP 
channel, sulfonylurea drugs will be quite an effective treatment for him/her, but it 
will also be easy to induce severe hypoglycemia. If we have enough information 
about these genes, we can avoid many hypoglycemic attacks occurring as an 
adverse reaction to sulfonylurea treatment.
 5.2 Glinides
Glinides also stimulate insulin secretion by acting on the KATP channel of 
beta cells. For repaglinide, polymorphisms of CYP2C8 and SLCO1B1 affect the 
plasma concentration22,23, while polymorphisms of KCNJ11 affect the therapeutic 
response24. There are relatively few pharmacogenetic studies on nateglinide 
compared to repaglinide, and only CYP2C9 and SLCO1B1 polymorphisms may 
affect the therapeutic response25,26.
5.3 Metformin
In data from the Diabetes Prevention Program (DPP), MATE1 gene 
polymorphisms were found to be associated with insensitivity to metformin27. 
GWAS showed that rs112112617 in the ATM locus was related to metformin 
treatment success28, while OCT1 is a gene that can influence the plasma 
concentration of metformin29-31. Since we do not know enough about how 
metformin works, these two genes (particularly ATM) will be used not only in 
personalized medicine, but also to investigate further mechanisms of diabetes 
etiology. 
5.4 Thiazolidinediones
Pharmacodynamic pharmacogenetic studies showed that genes encoding 
PPARgamma, lipoprotein lipase, adiponectin, and resistin were associated with 
the effect of pioglitazone therapy32,33, while a CYP2C8 polymorphism is associated 
with the plasma concentration of pioglitzaone34. 
Pharmacogenetic and pharmacogenomic data can provide more and more 
pharmacologic data on an individual (such as pharmacodynamics, pharmacokinetics, 
side-effects, etc.), which will make personalized pharmacotherapy more effective 
and decrease the adverse side-effects of drugs dramatically. 
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6. Using Personalized Medicine in Prevention
In Chapter 2, we identified approximately 50 genes related to T2D. The more 
the risk alleles one individual carries, the higher the chance he/she will suffer 
from T2D. However, this does not mean that we can predict the development of 
T2D only from genotypic data, since environmental factors and gene-environment 
interactions are also very important for its prediction. For example, Pima Indians, 
who are believed to have a susceptible genotype for T2D, have a much lower 
prevalence of T2D in northern Mexico than in the nearby southwest USA35. Hence, 
it is inappropriate for personalized medicine to predict the development of T2D 
only from genes related to the disease, although in population-based studies, the 
predictive effect will be more accurate when genetic factors are added to the other 
known predictive factors36. 
In contrast, lifestyle interventions and metformin have proved they can be 
used to prevent T2D effectively37. Since individual responses to metformin are 
related to genotype, it is better to choose metformin as a course of treatment for 
those individuals with alleles which can produce good effects from metformin. 
If an individual does not have a beneficial effect for metformin, he/she should be 
encouraged to adopt lifestyle interventions. However, we do not yet have enough 
data to prove whether successful lifestyle changes are related to certain genetic 
polymorphisms.
7. Personalized Medicine and Other “Omics” Data 
After high-throughput techniques were successfully used in genomics, similar 
techniques were applied to other fields, leading to transcriptomics, proteomics, 
lipidomics, metabolomics, etc. This means that we can now study the data of RNA, 
proteins, lipids, metabolites, etc., and we can also acquire epigenetic information 
to compose “epigenomic profiles” by similar techniques. Genomics provides us 
with information on someone’s DNA, which is relatively constant in an individual, 
but other “omics” data can give us more instant information at a certain time and 
state. The major problem today is that we cannot effectively explore all this data. 
With further progress in bioinformatics, and once we can decode various types of 
information, personalized medicine will become a much more powerful tool.
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8. Systems Biology: Research into Mechanisms and 
Personalized Medicine
As Margaret A. Hamburg and Francis S. Collins described38, “we are now 
building a national highway system for personalized medicine”, which means that 
our current research is similar to creating a network-like system with our “omics” 
databases for complex diseases, such as T2D. The challenge we are now facing is 
how to understand various types of data as an integrated system instead of millions 
of bits of detailed information. This is what systems biology methods can help us 
achieve.
In Chapter 1, we briefly introduced the ideas and goals of systems biology. 
Although systems science became a recognized discipline some 60 years ago, 
systems biology was only adopted by medical research less than 15 years ago, 
almost at the same time as the start of the HGP. 
In spite of many different definitions, systems biology approaches explore 
the huge complexity of biological systems. Compared to traditional methods, 
which are like “blind men feeling an elephant”, systems biology approaches aim 
to understand biological systems from the insights provided by systems science. 
These are similar to seeing the whole elephant as described by blind men. Since 
“omics” databases have provided us with information from various levels of human 
biology, the most important topic of systems biology has become how to discover 
the complex interactions.
Diabetes is a special disease for systems biology: glucose metabolism has its 
own negative-feedback systems and interacts with other feedback systems, such as 
lipid metabolism, the renin-angiotensin-aldosterone system, etc. Although we have 
a deep understanding of many details of the pathophysiological process of diabetes, 
it is far from enough for providing true personalized medicine. Thus, systems 
biology should be applied to the interactions of various kinds of information. In 
Chapter 6, we investigated the pleiotropic effects of lipid genes on glucose-related 
traits, and surprisingly found their direct, although weak, effect is to prevent blood 
glucose from increasing. This example reveals the complexity of genes and their 
actions, and it would be beneficial to investigate the further mechanisms. As more 
and more mechanisms are discovered, we can attain the “P4” level of medicine 
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(predictive, preventive, personalized, participatory) that systems biology offers, 
especially in relation to personalized medicine39. 
9. Conclusion
Although personalized medicine was first practiced in ancient times, it has 
been endowed with more and more connotations following the progress of modern 
science and technology. To be able to make a detailed classification of subgroups of 
patients is a big step towards offering personalized medicine. In contrast to earlier 
times, in the current post-GWAS era, we are now seeing huge amounts of “omics” 
data that we cannot yet understand, although we know it will eventually help us to 
offer personalized medicine. Our major challenge is how to “decode” these data, 
and this is dependent on the progress being made in systems biology, which aims 
at understanding the complexity of biological systems from insights gained by 
systems science.
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Summary
Type 2 diabetes (T2D) has become one of the most common chronic diseases 
worldwide in the past 20-30 years. Although the discovery of insulin was an epoch-
making achievement in the history of treating diabetes, we still face problems 
that insulin treatment cannot solve. And there are other, new, problems arising as 
side-effects from the use of insulin, for example insulin-induced hypoglycemia. 
The crucial issue is that we still cannot prevent the chronic and often severe 
complications of T2D, nor have we found an ideal way to prevent T2D developing. 
It is vitally important to investigate the mechanisms of T2D, so that we can 
fight the disease more effectively in the near future. In this thesis I look at novel 
mechanisms which may lead to prevention and treatment of T2D, and I describe 
investigations into some of these mechanisms from different pespectives, including 
important findings from genetic studies. 
In Chapter 1 I give a brief historical overview of the therapeutics of diabetes 
since insulin was introduced for clinical application. Insulin has significantly 
extended the lives of diabetes patients, but it has also provided clinical doctors and 
scientists with the chance to observe the outcome of chronic diabetic complications, 
which still remain unresolved. We need new drugs to prevent and treat T2D 
effectively, and therefore we need to investigate more of the mechanisms active in 
T2D, especially from the genetics viewpoint. Insulin can cause serious side-effects, 
which, although not as common as when it was first introduced as a treatment, still 
remain a problem. To solve these problems we need to discover the mechanisms of 
T2D and understand them better.
In Chapter 2, I report a review of 50 loci associated with T2D; these were 
mainly discovered by genome-wide association studies. The new candidate genes 
thus identified will be potential targets for anti-diabetic drugs in the future. Based 
on our current knowledge of their presumed molecular functions, we have classified 
them into various categories and discuss the relationships between the functions of 
each category and the current treatments for T2D.
In Chapter 3, I discuss whether hypertriglyceridemia and low-HDL cholesterol 
can be causal factors in the development of insulin resistance. If this is true, we 
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could prevent T2D by intervening in the hyper¬triglyceridemia and low-HDL 
cholesterol, which would represent good progress towards preventing T2D. I report 
a review of the evidence from epidemiological, genetic and intervention studies 
that supports this hypothesis.
Chapters 4 and 5 cover treatment of the side-effects caused by insulin 
therapy. In Chapter 4, I introduce CSII as a method of desensitization therapy as an 
alternative to multi-dose injections in T2D patients with insulin allergy. Although 
CSII has been used to treat insulin allergy for more than 20 years, the patients 
who could tolerate insulin therapy by CSII have to use it for the rest of their life. 
While our cases show success in desensitization by CSII, they also indicate a novel 
mechanism of T2D related to immune tolerance. In Chapter 5 I describe two cases 
with contrasting clinical symptoms, but due to similar mechanisms, with both 
related to anti-insulin antibody (AIA)-induced dysglycemia. Case 1 is a patient 
with severe hypoglycemia but no anti-insulin antibody could be detected in his 
serum, and he was eventually correctly diagnosed based on the results of column 
chromatography. Case 2 is a patient with severe hyperglycemia. His daily insulin 
dosage reached 650-800 IU, but his serum insulin was zero. We used a recovery 
test to show the existence of insulin in his serum. His treatments were similar to 
immune-suppressive regimens. Hence, we suggest a new classification for insulin-
related antibody-induced dysglycemia that is according to the pathophysiological 
mechanisms involved.
In Chapter 6, I report an investigation into the effects of lipid genes on 
glucose-related traits. In contrast to the strong correlation between dyslipidemia 
and glucose-related traits at a clinical level, the genetic components they share 
are surprisingly few. Genome-wide association studies have identified 95 loci that 
explain a substantial proportion of variance in blood lipids, which makes it possible 
to detect their effects on glucose-related traits. In this study, we focused on 95 lipid 
loci and tested their association collectively and individually with fasting glucose, 
glycated hemoglobin (HbA1c), and insulin resistance in two independent cohorts 
(10,995 subjects from LifeLines and 2,438 subjects from PREVEND). However, in 
contrast to their phenotypic relationship, the genetic predisposition to dyslipidemia 
showed a pleiotropic effect in lowering the levels of glucose traits. After adjusting 
for circulating lipid levels, higher TG, LDL and TC risk scores, and a lower HDL 
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risk score were correlated with lower levels of fasting plasma glucose, HbA1c 
and HOMA-IR. Furthermore, at single SNP level, 15 lipid loci showed pleiotropic 
association with glucose traits at P = 0.01 level and eight of them (CETP, MLXIPL, 
PILP, GCKR, APOB, APOE-C1-C2, CYP7A1 and TIMD4) had an opposing allelic 
direction on dyslipidemia and glucose levels. These unexpected results suggest a 
complex genetic regulation of the lipids and glucose metabolism, and a complex 
metabolic interplay between them.
In Chapter 7 I introduce a brief history of personalized medicine and discuss 
the contributions made by the research reported in this thesis to current and future 
personalized medicine strategies.
In conclusion, the work in this thesis shows our endeavors, in several respects, 
in investigating mechanisms for preventing and treating T2D. The paradoxical 
finding that a genetic predisposition to dyslipidemia shows a pleiotropic effect 
to lowering the levels of glucose traits is expected to lead to novel mechanistic 
insights into this disease. However, the effect sizes are still modest and they cannot 
be applied in clinical medicine yet. There is still much to do before the common, 
chronic disease of type 2 diabetes is defeated. 
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Samenvatting
Type 2 diabetes (T2D) is wereldwijd een van de meest voorkomende 
chronische ziektes geworden in de laatste 20-30 jaar. Alhoewel de ontdekking van 
insuline een gigantisch  succes is in de geschiedenis van diabetes behandeling, 
moeten we nog verschillende problemen overkomen die insuline nog niet 
heeft opgelost. Daarnaast zijn er een aantal nieuwe problemen opgedoken als 
bijwerkingen van insuline gebruik zoals bijvoorbeeld insuline geïnduceerde 
hypoglycemie. Het cruciale probleem is dat we de chronische en vaak ernstige 
complicaties van T2D niet kunnen voorkomen en we ook ideale methode ter 
preventie van T2D ontwikkeling nog niet hebben gevonden. Het is van vitaal 
belang om nieuwe mechanismen van T2D te onderzoeken zodat we T2D effectiever 
kunnen bestrijden in de nabije toekomst. In dit proefschrift bekijk ik nieuwe 
mechanismen voor preventie en behandeling van T2D, en beschrijf ik een aantal 
studies naar nieuwe mechanismen vanuit verschillende perspectieven inclusief 
belangrijke bevindingen vanuit genetische studies. 
In hoofdstuk 1 geef ik een kort historisch overzicht van diabetes therapie 
sinds de introductie van insuline in de kliniek. Insuline heeft het leven van diabetes 
patiënten significant verlengd, maar het heeft klinische dokters en wetenschappers 
de mogelijkheid gegeven om de complicaties die gepaard gaan met chronische 
diabetes te observeren. Deze complicaties zijn tot op dit moment nog niet opgelost. 
Om T2D effectief te voorkomen en behandelen is er een dringende behoefte aan 
nieuwe medicijnen. Hiervoor is meer onderzoek nodig naar mechanismen die 
actief zijn in T2D, vooral vanuit de genetisch oogpunt. Insuline kan serieuze 
bijwerkingen veroorzaken, die, alhoewel niet zo frequent als eerder, nog steeds een 
probleem vormen. Om oplossingen te vinden voor deze problemen moeten we eerst 
de mechanismen die aan T2D ten grondslag liggen ontdekken en ze beter begrijpen.
In Hoofdstuk 2 geef ik een overzicht van 50 loci geassocieerd met T2D die 
vooral ontdekt zijn door genoom-wijde associatie studies. De nieuw geïdentificeerde 
kandidaat genen zijn potentiële doelwitten van anti-diabetische medicijnen in de 
toekomst. Gebaseerd op onze huidige kennis van hun veronderstelde moleculaire 
functie, hebben we ze ingedeeld in verschillende categorieën en bespreken we de 
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relatie tussen functie van elke categorie en de huidige behandeling van T2D.
In hoofdstuk 3 bespreek ik of hypertriglycemie en laag-HDL cholesterol 
causale factoren kunnen zijn in de ontwikkeling van insuline resistentie. Als dit 
klopt, dan kunnen we een flinke voortgang boeken in de preventie van T2D door 
in te grijpen in de hypertriglycemie en laag-HDL cholesterol. Ik geef een overzicht 
van bewijs van epidemiologische, genetische en interventie studies die deze theorie 
ondersteunen.
Hoofdstuk 4 en 5 beslaan de behandeling van bijwerkingen veroorzaakt door 
insuline therapie. In hoofdstuk 4 introduceer ik CSII, een desensitisatie therapie als 
een alternatief voor de veelvoudige dosis injecties in T2D patiënten met insuline 
allergie. Alhoewel CSII al voor meer dan 20 jaar wordt gebruikt als behandeling 
voor insuline allergie, moeten de patiënten die insuline therapie door CSII tolereren 
het de rest van hun leven blijven gebruiken. Terwijl onze cases succes laten zien 
in desensitisatie door CSII, is er ook een indicatie van een nieuw mechanisme van 
T2D gerelateerd aan immuun tolerantie. In hoofdstuk 5 beschrijf ik twee cases 
met tegenstrijdige klinische symptomen, maar door een vergelijkbaar mechanisme 
die beide gerelateerd zijn aan anti-insuline antilichamen (AIA)-geïnduceerde 
dysglycemie. Case 1 is een patiënt met ernstige hypoglycemie maar anti-insuline 
antilichamen konden niet worden aangetoond in zijn serum. De patiënt werd 
uiteindelijk correct gediagnosticeerd op basis van kolom chromatografie. Case 2 
is een patiënt met ernstige hyperglycemie. Zijn dagelijkse insuline dosis bereikte 
650-800 IU, maar zijn serum insuline was nul. We hebben een herstel test gebruikt 
om de aanwezigheid van insuline in zijn serum aan te tonen. Zijn behandeling 
was vergelijkbaar met immuun onderdrukkende therapie. Derhalve stellen we 
een nieuwe classificatie van insuline-gerelateerde antilichaam- geïnduceerde 
dysglycemie voor op basis van betrokken pathofysiologische mechanismen.    
In hoofdstuk 6 doe ik verslag van een onderzoek dat in gaat op de effecten 
van lipiden op glucose-gerelateerde kenmerken. In tegenstelling tot de sterke 
correlatie tussen dyslipidemie en glucose-gerelateerde kenmerken op het klinische 
niveau, zijn de overeenkomsten op genetisch niveau verrassend beperkt. Genoom-
wijde associatie studies hebben 95 loci geïdentificeerd die een substantieel deel 
van de variatie in bloed lipiden verklaren, wat het mogelijk maakt om het effect 
op glucose-gerelateerde eigenschappen te detecteren. In deze studie hebben we 
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ons geconcentreerd op 95 lipiden loci en hebben we hun associatie gezamenlijk en 
individueel met gevast bloedsuikerspiegel, geglycosyleerde hemoglobine (HbA1c), 
en insuline resistentie in twee onafhankelijke cohorts (10.995 individuen van 
Lifelines en 2.438 individuen van PREVEND) bepaald. Echter, in tegenstelling 
tot hun fenotypische relatie, laat de genetische predispositie tot dyslipedemie een 
pleiotropisch effect zien in verlaging van glucose kenmerken. Na aanpassing van 
de circulerende lipide spiegels, werden hogere TG, LDL en TC risico scores, en een 
lagere HDL risico score gecorreleerd aan lagere spiegels van gevast bloedsuiker, 
HbA1c en HOMA-IR. Bovendien, op enkel SNP niveau, 15 lipide loci lieten een 
pleiotropische associatie zien met glucose kenmerken op P = 0.01 niveau en 8 
van deze genen (CETP, MLXIPL, PILP, GCKR, APOB, APOE-C1-C2, CYP7A1 en 
TIMD4) hadden een tegengesteld effect op dyslipidemie en glucose spiegels. Deze 
onverwachte effecten suggereren een complexe genetische regulatie en metabole 
interactie van lipiden en glucose metabolisme.
In hoofdstuk 7 introduceer ik kort de geschiedenis van persoonsgebonden 
geneeskunde en bespreek ik de bijdrage van onderzoek gerapporteerd in dit 
proefschrift aan huidige en toekomstige strategieën van persoonsgebonden 
geneeskunde.
In conclusie, het werk in dit proefschrift toont onze pogingen, om vanuit 
verschillende aspecten, mechanismen te onderzoeken ter preventie en behandeling 
van T2D. De paradoxale bevinding dat een genetische predispositie tot dyslipidemie 
een pleiotropisch effect op verlaging van glucose kenmerken laat zien, wekt de 
verwachting dat dit tot nieuwe mechanistische inzichten kan leiden van deze 
ziekte. Alhoewel, de effecten nog bescheiden zijn, kunnen ze op dit moment nog 
niet worden toegepast in de kliniek. Er is nog steeds veel te doen voordat de veel 
voorkomende chronische ziekte diabetes verslagen is.
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